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ABSTRACT 
Chih-Hong Wang 
Inhibition of renin angiotensin system improves leptin and insulin sensitivity, 
but causes severe anemia due to hypothyroidism 
(Under the direction of Nobuyuki Takahashi) 
An overactive Renin-Angiotensin System (RAS) is associated with the 
metabolic syndrome, and inhibiting RAS causes severe anemia.  Our previous study 
has demonstrated that mice lacking renin (Ren1c) are lean and insulin sensitive.  
However, to our surprise the Ren1c-/- mice have low circulating total thyroid 
hormones, and their plasma catecholamine levels were similar to those of wild type 
(WT) mice.  Although angiotensin II (Ang II) is suggested to regulate blood pressure, 
and insulin and glucose homeostasis, the precise mechanisms of its contribution to 
the metabolic syndrome are not completely understood. 
Obesity is often associated with leptin resistance, while leptin sensitivity is a 
potential therapeutic strategy to treat obesity. To establish the role of renin in the 
leptin sensitivity, and to investigate whether improved leptin sensitivity is responsible 
for lean and insulin sensitive phenotype of the Ren1c-/- mice, I generated mice lack 
of both renin and leptin (Ren1c-/-; ob/ob). The Ren1c-/-; ob/ob mice have lower body 
weight compared to the ob/ob mice at 3 months old despite similar food intake and 
   iv 
fat weight to body weight ratio.  They also have improved leptin sensitivity, 
demonstrated after leptin administration by larger decrease in body weight, body fat, 
and food intake in the Ren1c-/-; ob/ob mice relative to the ob/ob mice. In addition, 
the smaller body weight of Ren1c-/-; ob/ob mice are due to increased fecal fat 
excretion and fatty acid oxidation in the liver.  Moreover, The Ren1c-/-;ob/ob mice 
are  more insulin sensitive than the ob/ob mice as are the Ren1c-/- mice compared 
to wild type mice.  Improved leptin and insulin sensitivity by the absence of renin was 
recapitulated by a type 1 Ang II receptor (AT1R) blocker losartan.  Inhibiting AT1R 
improves leptin and insulin sensitivity, and may be useful in treating insulin 
resistance and leptin resistance in human obesity and diabetes. 
I next investigated whether the Ren1c-/- mice really have hypothyroidism, and 
if they have whether hypothyroidism contributes to anemia caused by inhibiting RAS.  
I provide evidence that the Ren1c-/- mice have tertiary hypothyroidism due to low 
expression of the hypothalamic TRH levels.  Tertiary hypothyroidism of the Ren1c-/- 
mice causes impaired erythropoiesis in bone marrow and results in severe anemia, 
while exogenous thyroid hormone (T3) corrects it.  Inhibition of AT1R or of Ang 
converting enzyme in WT mice recapitulated tertiary hypothyroidism and anemia in 
mice lacking renin. Although Ang II is suggested to stimulate erythropoiesis, my 
results demonstrated that hypothyroidism is the predominant cause of anemia 
induced by inhibiting RAS, and that without correcting hypothyroidism Ang II is not 
sufficient to correct anemia caused by RAS inhibition.  Thyroid hormone is a 
potential therapeutic strategy for anemia of patients with chronic renal failure, who 
are treated with inhibitors for RAS.  
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Background and Significance 
 
The metabolic syndrome 
The metabolic syndrome is a widely accepted concept that identifies the 
centrally obese patients with increased risk of cardiovascular diseases and 
diabetes.  The syndrome has a rising prevalence worldwide, which related largely 
to increasing obesity and sedentary lifestyles (1).  In the US approximately 34% 
of adults meet the criteria for the metabolic syndrome, and the syndrome is 3 
times more prevalent in males and females 40-59 years of age compared to 
those 20-39 years of age (2).  Patients with the metabolic syndrome have twice 
the risk of developing cardiovascular disease over the next 5 to 10 years relative 
to individuals without the syndrome (1).  The syndrome confers 5-fold risk for 
type 2 diabetes.  The metabolic syndrome is clinically characterized by several 
inter-related symptoms including obesity, dyslipidemia, high blood pressure, 
insulin resistance, impaired glucose tolerance or diabetes.  Each of these is a 
risk factor of cardiovascular disease and diabetes, but combinations of them 
greatly increase the risk of cardiovascular diseases (3).  However, there were 
many definitions of the metabolic syndrome, which led to confusion regarding 
how to identify patients with the syndrome (4, 5), leading to a confusion in clinical 
practice.  The main difference was that The International Diabetes Federation 
(IDF) had a threshold value for waist circumference as obligatory, whereas 
American Heart Association/National Heart, Lung, and Blood Institute 
(AHA/NHLBI) had it one of the factors but not obligatory.  Accordingly, IDF and 
AHA/NHLBI, jointed by the World Heart Federation, International Atherosclerosis 
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Society, and International Association for the Study of Obesity recently 
developed one unified definition (1) (Table 1.1): there should be no obligatory 
component, but waist measurement would continue to be a useful screening tool.  
Three abnormal findings out of 5 would qualify a person for the metabolic 
syndrome.  A single set of cut points would be used for all components except 
waist circumference.  Yet because the relation between waist circumference and 
cardiovascular disease and diabetes risk differs globally, the definition for waist 
circumference remains unsettled.  However, the molecular mechanism of the 
pathogenesis of the metabolic syndrome is not well understood. 
 
The Renin-Angiotensin System and the metabolic syndrome 
The renin angiotensin system (RAS) is one of the most important systems 
that regulate cardiovascular and fluid homeostasis (Fig. 1.1).  Angiotensins can 
also act as neurotransmitters, regulating blood pressure (BP), memory, cognition 
and stress in the brain (6-8).  The RAS recently has been implicated in the 
metabolic syndrome.  Ang II induces adipogenesis (differentiation into adipocytes) 
(9, 10) and lipogenesis (triglyceride storage in adipocytes) in vitro (11).  The 
effects of Ang II on adipose tissue are mediated by Ang II type 1 and type 2 
receptors(12).  However, the in vivo role of RAS in the metabolic syndrome has 
been unclear.   
Renin, released from the kidney juxtaglomerular (JG) cells, is a rate-
limiting enzyme in angiotensin II (Ang II) production.  Renin cleaves the liver- and 
adipose-tissue-derived angiotensinogen (AGT) to form inactive angiotensin I  
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Table 1.1 Criteria for clinical diagnosis of the metabolic syndrome. 
 Categorical cutpoints 
Increased waist circumference* 
 
Increased triglycerides (drug treatment for 
elevated TG is alternate indicator†) 
 
Reduced HDL cholesterol (drug treatment for 
reduced HDL cholesterol is alternate indicator†) 
 
Increased blood pressure (antihypertensive drug 
treatment in patient with history of hypertension is 
alternate indicator) 
 
Increased fasting glucose‡ (drug treatment of 
increased glucose is alternate indicator) 
Population-specific and country-specific 
definitions  
 
≥150 mg/dL (1.7mmol/L) 
 
 
<40 mg/dL (1.0 mmol/L) in men 
<50 mg/dL (1.3 mmol/L) in women 
 
Systolic ≥130 and/or diastolic ≥85 mm Hg 
 
 
> 100 mg/dL (5.5 mmol/L) 
  
*It is recommended that the IDF cutpoints be used for non-Europeans and either the IDF or 
AHA/NHLBI cutpoints used for people of European origin until more data are available.  †Most 
commonly used drugs for increased triglycerides and reduced HDL cholesterol are fibrates and 
nicotinic acid.  A patient on one of these drugs can be presumed to have high triglycerides and 
low HDL.  Use of high-dose ω-3 fatty acids presumes high triglycerides.  ‡Most patients with type 
2 diabetes will have the metabolic syndrome by the proposed criteria. 
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Figure 1.1 The Renin-angiotensin system (RAS). Angiotensin II effects are 
predominately mediated by angII type 1 receptor (AT1R). In addition to the 
classical RAS, ACE2 and (pro)renin receptor are new players of this system. 
  
6 
(Ang I) (13). The angiotensin-converting enzyme (ACE), which is mainly 
expressed in the endothelium, then removes two C-terminal amino acids and 
generates active peptide Ang II.  Interestingly, the human ACE insertion/deletion 
(ID) polymorphism does not affect BP despite the powerful antihypertensive 
effects of ACE inhibitors (reviewed in (14, 15)), although mild increase in ACE 
causes exacerbation of diabetic nephropathy (see the section on ACE). The 
majority of the biological effects of Ang II, including BP elevation, are mediated 
by the type 1 Ang II receptor (AT1R).  An Ang II negative-feedback mechanism 
inhibits the expression and secretion of renin.  Treatments of hypertension often 
involve the inhibition of RAS with Ang receptor blockers (ARB), ACE inhibitors, or 
renin inhibitors, all of which disrupt this negative-feedback mechanism and 
increase renin levels. 
In addition to these classical RAS components, several new molecules 
have been discovered in recent years.  A homolog of ACE, ACE2, was 
discovered and shown to convert Ang II to Ang(1-7) (16).  Santos et al. 
discovered that the receptor for Ang(1-7) is the Mas proto-oncogene, and that 
this ACE2–Ang(1–7)–Mas pathway counteracts the effects of Ang II (17).  
Furthermore, Nguyen et al. discovered the (pro)renin receptor (PRR) in 2002 (18, 
19).  This receptor is expressed in many tissues including brain, adipose tissue, 
endothelial cells, vascular smooth muscle cells, and kidney.  PRR binds and 
activates prorenin.  This newly discovered RAS component likely impacts local 
Ang II effects in cardiovascular diseases and the metabolic syndrome.  However, 
the detail mechanism of how RAS modify the metabolic phenotype is not known. 
 Renin in humans and in mice 
 
Renin is an important enzyme for regulation of BP and cardiovascular 
homeostasis. Cleavage of AGT to Ang I by renin is a rate-limiting step of Ang II 
production (20). Renin is secreted from juxtaglomerular cells, which are modified 
smooth muscle cells of the afferent arterioles in the kidney. In Spanish populations, 
individuals with the GG genotype at the rs5707 intron 4 polymorphism of renin have 
significantly higher BP compared to those with the TT or TG genotype (21). Individuals 
with GG genotype of the missense mutation in exon 9 (G1051A) have higher plasma 
renin activity, and this polymorphism may be involved in the etiology of hypertension 
(22). 
 Renin is encoded by a single gene in humans, rats, and some strains of 
laboratory mice such as C57BL/6, BALB/c, and C3 (Fig.1. 2). However, some laboratory 
mouse strains (eg. 129, DBA/2J) have 2 renin genes (Ren2 and Ren1d) in tandem on 
the same chromosome due to natural duplication of the gene.  The regulation of 
expression and tissue specificity of Ren1d and Ren2 are different (23), which 
complicates renin studies. Mice lacking either Ren1d or Ren2 exhibited no change in 
BP or any other apparent phenotype (24, 25), although homozygous mice with Ren1d 
replaced with GFP had lower BP (26).   
 Since C57BL/6 mice, like humans, have only one renin gene, Ren1c, and are 
susceptible to diet-induced obesity, they are more suitable for research involving 
changes in renin expression and the metabolic syndrome (23). Because of the difficulty 
in generating mice by gene targeting with C57BL/6 embryonic 
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Figure 1. 2 Mouse renin genes. Renin is encoded by a single gene in human, 
rats and some of strains of laboratory mice such as C57bl/6, BALB/c, and C3. 
However, some laboratory mouse strains (eg. 129, DBA/2J) have 2 renin genes 
(Ren2 and Ren1d) in tandem on the same chromosome through natural 
duplication. Tissue expression of these genes is different. 
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stem cells, Yanai et al. disrupted the Ren1c gene using TT2 ES cells derived from an F1 
hybrid between C57BL/6 and CBA (27). The authors demonstrated that these 
homozygous mutant mice had undetectable levels of plasma renin activity and plasma 
Ang I. In addition, the BP of these animals was lower than wild type by 20-30 mm Hg. 
The knockouts also had increased urine and drinking water volume and hydronephrosis, 
as observed in the Agt-/- mice. Abnormal granular cell layers in the hippocampus, as 
observed in the Agt-/- mice(28), were absent in mice lacking renin(27).   
 We have independently generated mice lacking Ren1c using embryonic stem 
cells from C57BL/6N mice (20). Our Ren1c-/- mice have low BP and undetectable levels 
of plasma renin, Ang I, and Ang II (20).  Similar to the Ace-/- mice, our Ren1c-/- mice 
are anemic, as reflected by their low hematocrit (32 ± 3% vs. 45 ± 5 % in wild-type litter 
mates). Administration of Ang II (200 ng/kg/min) using an osmotic minipump restored 
BP levels in the Ren1c-/- mice to wild-type levels, but preexisting damage to the kidney 
medulla by hydronephrosis prevented restoration of the ability to concentrate urine.  
Heterozygous Ren1c+/- mice are normal with wild type levels of BP, and their kidney 
renin mRNA expression and plasma renin concentration are indistinguishable from 
those of wild type control mice (20). 
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Metabolic phenotype of mice lacking renin 
We have recently investigated the role of renin in the metabolic syndrome and 
demonstrated that the Ren1c-/- mice have less than 50% of wild-type adipose tissue 
weight, which is consistent with the reduced fat volume of the knockouts analyzed by 
MRI. These mice were resistant to diet-induced obesity, although there were no 
changes in food intake (29). The Ren1c-/- mice had smaller adipocytes in all adipose 
tissue tested, including white adipose tissue (WAT) and brown adipose tissue (BAT), 
and reduced hepatic triglyceride.  Based on energy balance, the lean phenotype seen in 
these mice should be due to either increased energy expenditure and/or increased fecal 
energy loss (Fig. 1. 3). Indeed, the null mice displayed gastrointestinal loss of dietary fat 
as indicated by a higher steatocrit and a lower daily fat absorption (Table 1.2).  
 Indirect calorimetry showed that, although physical activity was the same in the 
Ren1c-/- and wild-type mice, the Renc1-/- mice displayed increased heat generation 
and lipid combustion, as indicated by their low respiratory quotient (RQ). These mice 
require a smaller amount of insulin to maintain the same or lower plasma glucose levels 
relative to wild types. These results suggest a role for renin in the pathogenesis of diet-
induced obesity and insulin resistance. Inhibition of renin may provide a good 
therapeutic target in the metabolic syndrome. 
 Other investigators have demonstrated that mice lacking Agt or Ace also have 
low BP, lean body type, and resistance to diet-induced obesity. Interestingly, however, 
these mice are not as lean as mice lacking renin (Table1. 2).  
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Figure 1.3 The energy flow of  Ren1c-/- mice. Mice lacking renin are lean and 
resistant o diet-induced obesity due to increased energy expenditure and 
increased fecal energy loss.   
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Table 1. 2 Metabolic phenotype of mice lacking renin, AGT and ACE. 
 
 
 
 
 
RQ: respiratory quotient, UCP1: uncoupling protein 1, NS, not significantly different from 
wild type controls. 
 
 
 
 
 
 
 
  
 % body 
fat 
(%WT) 
food 
intake 
 
fecal 
fat 
 
Locomotor 
activity 
 
heat 
generation 
 
RQ 
 
UCP1 
 
renin 
 
Ren1c-/-  
 
45% NS High NS High  Low High  absent 
Agt-/-   
 
76% NS NS High NS  NS High  
Ace-/-  
 
53% NS NS NS NS NS NS High  
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The Ren1c-/- mice also display a unique increase in fecal fat excretion, heat generation, 
uncoupling protein (UCP1) expression in brown adipose tissue (BAT), and a reduced 
respiratory quotient (RQ), which were not observed in the Agt-/- and the Ace-/- mice 
(Table 1.2). Because BAT is required for most non-shivering thermogenesis in rodents, 
these data suggest that the Ren1c-/- mice generate more heat by combusting fat in BAT.  
The Agt-/-, Ace-/- and Ren1c-/- mice have no detectable levels of Ang II, but different 
from the Ren1c-/- mice, both Agt-/- and Ace-/- mice have very high levels of renin due to 
disruption of a negative feedback mechanism.  Accordingly, the lack of Ang-
independent effects of renin likely contributes to decreased adiposity by decreasing 
dietary fat absorption and increasing heat generation.  
 
(Pro)renin receptor 
The (pro)renin receptor (PRR) is a single transmembrane protein of 350 amino 
acids. This specific renin receptor, discovered by Nguyen and colleagues in 2002, has 
dual functions (Fig. 1.4): (i) increases catalytic activity of the PRR-bound prorenin to 
produce Ang I (30); and (ii) activates MAP kinases independently of Ang II (31). When 
prorenin binds PRR, a conformational change occurs in the prorenin molecule 
conferring full enzymatic activity and the ability to produce Ang I without undergoing 
proteolytic cleavage (32). Prorenin makes up 70-90% of total circulating renin (33), but it 
will not be converted to renin (34), which is synthesized only in the kidney. The binding 
of prorenin and renin to the cell surface in tissues is of pivotal importance in the  
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Figure 1.4 Classical RAS pathway and novel effects of (pro)renin mediated 
by  a (pro)renin receptor. Prorenin and renin effects via PRR include Ang II-
dependent and independent actions. Ang II- independent actions involve 
increased catalytic activity of the PRR-bound prorenin to generate Ang I from 
AGT. Ang II-indepent action involves intracellular signaling that triggers activation 
of an extracellular signal related protein kinase (ERK1/2) pathway. 
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physiology of local RAS in organs, since it provides a mechanism to generate Ang II 
locally in excess of the Ang II that is produced in plasma. Nguyen and colleagues also 
demonstrated that the binding of renin to its receptor increases the conversion rate of 
AGT to Ang I by four-fold (31). In addition, both renin and prorenin bind to the PRR with 
similar affinity and activate the MAP kinase pathway (31, 33, 35). 
 Ang-independent effects of renin or prorenin on adiposity, human renin transgenic 
(hREN Tg) mice weigh twice as much as wild-type mice at 60 weeks of age and display 
normal BP (36). BP and plasma Ang II levels in hREN Tg mice are indistinguishable 
from wild-type mice, while double transgenic mice harboring both hREN Tg and hAGT 
Tg, have high BP and Ang II levels (37), suggesting that human renin does not generate 
Ang I from mouse AGT.  Indeed, when incubated with plasma from our Ren1c-/- mice, 
which contains high levels of mouse AGT, exogenous recombinant human renin (10-12~-
8
 M) does not cause Ang I production even at a concentration 10,000 times higher than 
normal physiological levels of mouse renin, although both human and mouse renin 
equally activates ERK1/2 in mouse vascular smooth muscle cells (Fig. 1.5).  Thus, the 
obesity phenotype observed in human renin transgenic mice underscores the 
importance of an Ang-independent role of renin in regulating body weight possibly via 
(pro)renin receptor.   
Abnormal signaling from the (pro)renin receptor is involved in cardiac fibrosis 
(38), nephrosclerosis (39), and microvascular complications (40). Binding of PRR to its 
receptor in renal glomerular mesangial cells and cardiomyocytes activates ERK and p38, 
respectively, independent of Ang II (31, 41). The (pro)renin receptor is highly conserved 
in human, mouse, rat, and other species (33), and our data show that human renin and 
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mouse renin are equally effective at activating MAPK in mouse cells (Fig. 1. 5). A renin 
inhibitor, aliskiren, inhibits Ang I synthesis and is widely used for treatment of 
hypertension (42).  Ichihara and colleagues proposed using a 10-amino acid sequence 
of the prorenin prosegment, termed “handle region peptide (HRP)”, and demonstrated 
that HRP blocks binding of prorenin to PRR (40).  These authors showed that 
subcutaneous administration of HRP to streptozotocin-induced diabetic rats decreased 
renal content of Ang I and Ang II, and inhibition of diabetic nephropathy (40).  However, 
Feldt et al. were not able to block prorenin and renin-induced ERK1/2 activation by HRP 
or aliskiren (35). It is possible that HRP efficacy in vivo depends on an undefined 
mechanism rather than competitive antagonism for the PRR.   
 
Ang II receptors 
 
Ang II has two receptors, the Ang II type I receptor (AT1R) and the Ang II type II 
receptor (AT2R). Both receptors are G-protein-coupled receptors with seven 
transmembrane domains (43). The AT1R and AT2R subtypes have similar Ang II-
binding properties but different genomic structure and localization, as well as tissue-
specific expression and regulation.  
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Figure 1.5 Human (h-) renin does not generate Ang I from mouse (m-) AGT. 
Human renin does not generate Ang I from mouse AGT. However, h-renin 
activates MAPK in mouse vascular smooth muscle cells possibly via m-(pro)renin 
receptor. *p<0.05 vs. control.  
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The AT1R is responsible for the classical actions of Ang II such as vasoconstriction, 
aldosterone release from the adrenal zona glomerulosa, salt retention in the renal 
tubules, and stimulation of the sympathetic nervous system. AT2R plays an important 
role in the growth, differentiation, and regeneration of neuronal tissue (44, 45).   
 The A1166C polymorphism in the 3’UTR of AT1R is strongly associated with the 
incidence of essential hypertension and increased coronary artery vasoconstriction (46), 
cardiac hypertrophy (47), and diabetic nephropathy (48), and predicts the development 
of the metabolic syndrome (49, 50).  Humans have only one AT1R, but mice have two 
AT1R subtypes: AT1aR and AT1bR (Agtr1a and Agtr1b) (51).  Their signaling 
mechanisms are almost identical but the regulation of their expression differs. AT1aR is 
dominant in most tissues relevant to the cardiovascular system, while AT1bR is only 
expressed in pituitary glands, testes, and adrenal gland (52, 53). The type 2 receptor is 
highly and widely expressed during fetal development; but in adults, its expression is 
confined to the adrenal medulla, uterus, ovary, vascular endothelium and certain areas 
of the brain.  AT2R appears to counterbalance some of the effects of AT1R by inducing 
vasodilatation, growth arrest and apoptosis (Fig. 1. 6). Deletion of AT1aR causes 
hypotension and an increase in renin which leads to a profound increase in Ang II. 
Interestingly, Agtr1b-/- mice exhibit normal BP and pressor response to Ang II (54), 
whereas mice lacking both AT1aR and AT1bR have low BP similar to Agt-/- mice (55).  
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Figure 1.6 Ang II receptors. Type 1 receptor (AT1aR and AT1bR in mice) 
mediates the majority of Ang II effects, and regulates muscle contraction, 
inflammation, insulin levels and cell proliferation, while AT2R regulates apoptosis. 
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The dual null Agtr1a-/-; Agtr1b-/- mice also develop abnormal renal phenotypes identical 
to those observed in the Agt-/-, Ace-/-, and Ren1c-/- mice.  In contrast, mice lacking the 
AT2R gene do not exhibit these phenotypes. BP in the Agtr2-/- mice is approximately 3-
17 mmHg higher than in wild-type mice (56).  
 When the Agtr2-/- mice were treated with deoxycorticosterone acetate (DOCA) 
and salt, it became obvious that they are salt sensitive (56).  The Agtr2-/- mice show 
congenital anomalies of the kidney and urinary tract (CAKUT) as observed in humans, 
namely lack of interstitial fibrosis at birth, with some hypoplastic, cystic, and/or 
dysplastic parenchyma (57). They also identified a single nucleotide transition (A-1332G) 
in intron 1 of the AGTR2 gene in patients with CAKUT, which decreases the amount of 
AGTR2 mRNA expression. 
Kouyama et al. have shown that the Agtr1a-/- mice are lean, resistant to diet-
induced obesity, with improved insulin sensitivity (58). These authors also found that 
these mutant mice have increased sympathetic activity and energy expenditure, 
probably due to the activation of AT1bR. These observations suggest that Agtr1a-/- 
mice are protected from some components of the metabolic syndrome. In addition, 
blocking AT1R with losartan activates the insulin-mediated IRS1/PI3/GLUT4 cascade in 
skeletal muscle and white adipose tissue, leading to improved glucose tolerance and 
insulin sensitivity (59).  AT2R is expressed in the heart, kidney, brain, uterus, and 
adipose tissue (60). AT2R expression in adipose tissue is low, but AT2R seems to 
mediate Ang II stimulation of adipose tissue development (61). AT2R can induce 
production and release of prostacyclin from adipocytes, which in turn stimulates 
differentiation of preadipocytes (62).  Mice lacking Agtr2 have increased glucose uptake 
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in adipose tissues (62). Laurent et al. have shown that the Agtr2y/- mice (AT2R gene is 
on the X chromosome) have normal adiposity but display small adipocytes at an 
increased number (63). These authors found that mice lacking Agtr2 have increased 
lipid oxidation, which is caused by increased expression of fatty acid translocase, 
uncoupling protein-3, peroxisome proliferation activated receptor (α, δ), and carnitine 
palmitoyl transferase-1 (CPT-1). In agreement with their lean phenotype, the Agtr2y/- 
mice have decreased food intake and increased total energy expenditure. These 
studies indicate that inhibition of AT1R and AT2R improves insulin sensitivity and 
causes fat loss, which is in agreement with the involvement of Ang II in the insulin 
signaling pathway and in the control of adipose tissue metabolism. 
 
Pharmacological inhibition of RAS  
Blocking RAS with ACE inhibitors or Ang receptor blockers (ARB) has become a 
crucial element of cardiovascular and renal medicine. Clinical studies indicate that 
ARBs and ACE inhibitors prevent the onset of diabetes and improve insulin sensitivity 
(64, 65). In mice, blocking AT1R improves insulin sensitivity and other diabetes 
symptoms due to increased glucose uptake in skeletal muscle and white adipose tissue 
(66). This is due to enhanced insulin signaling and GLUT4 translocation to the plasma 
membrane (66). Treatment with ARBs (losartan, or candesartan) does not reverse 
diabetes, but it effectively improves glucose tolerance and protects β-cell function by 
attenuating oxidative stress, islet fibrosis, sparse blood supply, and disruption of 
ultrastructure in a dose-dependent and BP-independent manner (67). In addition, ARBs 
may protect the pancreas in type II diabetic animal models with enhanced insulin 
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secretion (68). Furthermore, in diabetic models, some ARBs induce adipocyte 
differentiation by increasing peroxisome proliferator-activated receptor-gamma (PPARγ) 
in adipose tissue (69). Accordingly, ARBs could be a novel form of treatment for the 
metabolic syndrome and associated pathological disorders. 
 Moreover, aliskiren is a novel renin inhibitor for the treatment of hypertension 
(70). This renin inhibitor has protective effects on endothelial function and 
atherosclerotic changes.  Lu et al. showed that aliskiren resulted in striking reductions of 
atherosclerotic lesion size in both the aortic arch and the root in fat-fed LDL receptor–
deficient (Ldlr–/–) mice (71).  Furthermore, cotreatment with aliskiren and an ARB has 
additive protective effects (72). Thus, aliskiren may also be a promising protective drug 
for patients with hypertension and diabetes (73).  
 
Leptin resistance and the Renin Angiotensin System 
Obesity associated with leptin resistance results in elevated blood leptin levels. 
Leptin is a 16 kDa polypeptide hormone secreted by adipose tissue which conveys 
information about energy storage and availability to the hypothalamus. The 
hypothalamus is a critical area that senses and integrates various neuronal, hormonal 
and nutrient-related signals. (74). Leptin signals in the hypothalamus by binding to leptin 
receptor (LRb), and activating the associated tyrosine kinase JAK2 (Janus kinase 2) 
phosphorylates residues Tyr985 and Tyr1138 of LRb, and recruits, and activates the 
transcription factor STAT3 (signal transducer and activator of transcription 3) within the 
LRb cytoplasmic tail(75). Reduced activation of STAT3 phosphorylation in response to 
leptin is evident in the arcuate nucleus of the hypothalamus and induces leptin 
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resistance and diet-induced obesity (DIO) via SOCS3 that has assessed DIO and leptin 
resistance (76). Increased hypothalamic SOCS3 levels are associated with leptin 
resistance including hyperplasia, hyperleptinemia and accumulation of triglyceride in the 
liver and skeletal muscle (76). Mice with haploinsufficiency of SOCS3, or those with 
neuronal deletion of SOCS3 have demonstrated improved leptin and insulin sensitivity, 
and resistance to diet-induced obesity (77, 78). The efficacy of leptin therapy in obese 
humans, however, has been in a large frustration due to the development of leptin 
resistance. Thus, targeting molecules required for the development of leptin resistance 
is a potentially powerful therapeutic approach for anti-obesity.  
Moreover, leptin resistance is a hallmark and key determinant of obesity, and 
leads to an accumulation of triglyceride (TG) not only in adipose tissues but also in the 
liver, skeletal muscle, and other peripheral tissues- leading to obesity, insulin resistance, 
and non-alcoholic steatohepatitis (NASH). Enhanced leptin sensitivity is associated with 
improved glucose homeostasis (79). Leptin activates JAK2, a cytoplasmic tyrosine 
kinase that binds to LRb and activates STAT3 transcription factor. STAT3 induces 
suppressor of cytokine signaling-3 (SOCS3) expression, which inhibits leptin signaling 
by JAK2 inactivation (80). In addition, Ang II increases SOCS3 via JAK-STAT3 pathway 
in the hypothalamus, and heart, while inhibition of Ang II by ARB losartan causes 
decreased leptin signals (Fig 1.7) (81). However, relationship between Ang II and leptin 
remains unclear. Accordingly, I investigated whether Ang II plays an important role in 
the regulation of food intake and leptin sensitivity via JAK2/STAT3 pathway. 
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Leptin and hypothalamic neuropeptides: POMC, NPY and AgRP  
Leptin can regulate food intake and energy expenditure by modulating orexigenic 
and anorexigenic signaling pathway in the hypothalamus (Fig 1.7). Binding of leptin to 
LRb decreases food intake and increases energy expenditure.  LRb is highly expressed 
in two groups of neurons in the arcuate nucleus (ARC) of the hypothalamus: one group 
expresses either orexigenic neuropeptide Y /Agouti-related protein (NPY/AgRP), and 
the other group expresses anorexigenic pro-opiomelanocortin POMC (82). Stimulating 
POMC neurons by leptin results in inhibiting NPY/AgRP neurons and decreasing food 
intake, body weight, and AMPK activity as well as increasing energy expenditure and 
expression of thyrotropin releasing hormone (TRH) (83) (Fig 1.7).  POMC neurons have 
been considered as the primary cell type for mediating leptin effect through alpha-
melanocyte-stimulating hormone (α-MSH), which is a cleavage product of POMC.   
α-MSH belongs to a melanocortin group including ACTH, α-MSH, β-MSH and γ-
MSH(84). Anorexigenic effect of lepitn is mediated by binding of α-MSH to MC4 
receptor (MC4R) resulting in suppression of NPY/AgRP neuron, increased energy 
expenditure, decreased food intake and TRH synthesis (85). Thus, POMC increases 
metabolic rate and energy expenditure by stimulating hypothalamic TRH synthesis(86).   
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Figure 1.7 Leptin signaling pathway regulates AMPK activity, food intake and 
energy expenditure via anorexigenic, and orexigenic neuropeptides in the 
hypothalamus. Leptin inhibits AMPK activity and food take and increases energy 
expenditure directly or indirectly via STAT3 phosphorylation, and increases the 
expression of anorexigenic neuropeptides POMC, and decreases the expression of 
orexigenic neuropeptides AgRP and NPY. 
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Moreover, several studies have shown that α-MSH via melanocortin 4 receptor 
(MC4R) increases TRH synthesis in the paraventricular hypothalamic nucleus (PVN) 
(85).  Leptin can increase metabolic rate and energy expenditure by activating POMC 
neurons, which in turn increases synthesis of hypothalamic TRH, leading to elevated 
thyroid hormones (83).  Accordingly, fasting reduces plasma leptin level, which leads to 
increased food intake and diminished metabolic rate and energy expenditure by 
decreasing thyroid hormones(85), whereas ablation of POMC neurons leads to 
profound obesity(84) and reduced circulating thyroid hormone levels due to decreased 
hypothalamic TRH gene expression(87). In addition, leptin improves glucose tolerance, 
and increases glucose transporter and nitric oxide expression by PI3K signaling 
pathway(88). Thus, leptin sensitivity could provide an avenue for fighting diabetes and 
obesity.  However, whether RAS modulates the expression or function of POMC, NPY, 
and AgRP in the hypothalamus is not well known. 
 
A central role for neuronal AMP-activated protein kinase (AMPK) for food intake 
and energy expenditure 
AMP-activated protein kinase (AMPK) plays an important role in the regulation of 
cellular energy metabolism by phosphorylation of key enzymes in the metabolic 
pathways, such as acetyl–coenzyme A carboxylase (ACC)(89). In mammalian, AMPK is 
a trimeric enzyme including a catalytic α subunit (63 kDa) and non-catalytic β and γ 
subunits. Multiple isoforms of each mammalian enzyme exist (α1, α2, β1, β2, γ1, γ2, γ3), 
each encoded by a different gene (90). The β subunits have a molecular mass in 38 
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kDa (β1) and 34 kDa (β2), whereas the three γ isoforms have molecular masses of 37 
kDa (γ1), 63 kDa (γ2) and 55 kDa (γ3).(91) AMPK complexes containing α2 (the first 
catalytic isoform to be cloned) (89) is predominately expressed in the hypothalamus, 
skeletal and cardiac muscle, whereas equal levels of α1 and α2 complexes are present 
in the liver.  
AMPK functions have been extensively investigated in the hypothalamus, liver, 
and skeletal muscles(89). In the hypothalamus, AMPK activity is altered by hormonal 
and metabolic signals and mediates the feeding response to leptin and insulin (Fig 1.7 
and 1.8). Hypothalamic AMPK signaling plays an important role in the control of food 
intake (92, 93), particularly in the arcuate nucleus (ARC) integrates peripheral nutritional 
and feeding signals. When energy intake exceeds expenditure, the expression of 
orexigenic neuropeptides, such as AgRP and NPY, decreases. Conversely, the 
expression of anorexigenic neuropeptides, such as POMC, increases. Opposite 
changes occur when energy expenditure exceeds energy intake (Fig 1.8). Mice lacking 
AMPK function in POMC neurons became obese because they reduced their energy 
expenditure and increased their food intake after fasting (94). By contrast, mice lacking 
AMPK function in AgRP neurons showed age-dependent decrease in body weight (94) 
and the anorexigenic signals (POMC) inhibit AMPK activity in orexigenic AgRP/NPY 
neurons and increases energy expenditure (93). This suggests that leptin indirectly 
inhibits hypothalamic paraventricular nucleus AMPK activity via α-melanocyte–
stimulating hormone (α-MSH) release and activation of melanocortin 3/4 receptors 
(MC3/4Rs) (93).  
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Figure 1.8 AMPK mediates leptin and insulin to regulate food intake and fatty acid 
oxidation in the hypothalamus. Increase orexigenic neuropeptides  AgRP and NPY, 
and decrease the expression of  anorexigenic neuropeptides POMC by AMPK, which 
also regulates fatty acid oxidation via acetyl-CoA carboxylase (ACC). 
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Moreover, in the peripheral tissues, AMPK acts as a counter-regulatory 
mechanism that switches off ATP-consuming processes while switching on catabolic 
processes that produce ATP and restore the AMP: ATP ratio. AMPK stimulates 
pathways, which increase energy production(95)(glucose transport, and fatty acid 
oxidation) and switches off pathways, which consume energy (lipogenesis, protein 
synthesis, and gluconeogenesis)(95). Adiponectin and leptin as well as hypoglycemic 
drugs activate AMPK in the liver and skeletal muscle.  However, whether RAS 
modulates AMPK activity is not fully understood. 
 
Uncoupling protein-1 (UCP-1) and energy expenditure 
Mitochondrial UCP-1 is a 32 kDa transmembrane protein which discharges the 
proton gradient for oxidative phosphorylation(96). UCP-1 is a major regulator of heat 
generation, allowing substrate oxidation with a low rate ATP production.  It is 
predominately expressed in the brown adipose tissue (BAT), which is responsible for 
cold adaptation/acclimation, increases fatty acid oxidation and electron transport chain 
activity resulting in heat production by this tissue. This adaptive process is termed non-
shivering thermogenesis(97). 
 In addition, the activation of UCP1 is accompanied by a dramatic increase in 
lipolysis and mobilization of lipids in white adipose tissue depots.  In mice, increased 
content of UCP1 in adipose tissue is strongly linked to protection against diet-induced 
obesity(98), which is consistent with  UCP-1 knockout mice.  Ablation of UCP-1 in mice 
induces obesity with decreased oxygen consumption and energy expenditure at 
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thermoneutrality (at 30°C )(99) . Therefore, UCP-1 protein plays an important role in 
diet-induced thermogenesis and can be a target molecule for treatment of obesity.  
 
UCP1 and RAS 
BAT UCP-1 is required for most non-shivering thermogenesis to combat 
obesity(96) and the Agt-/-, Ace-/- , Agt1a-/- and Ren1c-/- mice are resistant to diet-
induced obesity(58, 100-102). However, Agt-/-, Ace-/- and Agt1a-/- mice have BAT 
UCP-1 expression comparable to WT mice, whereas the Ren1c-/- mice have an 
increase of BAT UCP-1 expression and generate more heat by combusting fat in BAT. 
Although the Agt-/-, Ace-/- and Ren1c-/- mice have no detectable levels of Ang II, 
different from the Ren1c-/- mice(102), both Agt-/- and Ace-/- mice have very high levels 
of renin due to disruption of a negative feedback mechanism.  Accordingly, lack of Ang-
independent effects of renin likely contributes to decreased adiposity by increasing heat 
generation.  
 
Thyroid hormone and RAS 
UCP1 is predominately regulated by sympathetic nervous system (SNS) and thyroid 
hormone (TH) (96).  TH plays a critical role in development, growth, and cellular 
metabolism. TH production is controlled by a complex mechanism of positive and 
negative regulation. Hypothalamic TRH stimulates TSH secretion from the anterior 
pituitary, which in turn promotes TH synthesis and release from the thyroid gland. The 
synthesis of TRH and TSH gene expression is inhibited at the transcriptional level by 
TH, which also inhibits posttranslational modification and release of TSH (Fig 1.9). 
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Although opposing TRH and TH inputs regulate the hypothalamic-pituitary-thyroid axis 
(HPT), TH negative feedback at the hypothalamus plays a critical regulator of TH levels 
(103).  
Recently, the role for TRH in TH feedback of the HPT axis has been demonstrated. 
Mice lacking either TRH (TRH-/-), the β-isoforms of TH receptors (TRβ-/-), or both 
(double KO) were generated (104). As previously reported, TRβ-/- mice have 
significantly increased TH, TSH and TRH levels compared with wild-type mice. In 
contrast, double KO mice had reduced TH, TSH and TRH levels compared with control 
animals. Unexpectedly, hypothyroid double KO mice also failed to increase plasma TSH 
levels, and pituitary TSH immunostaining was markedly reduced compared with all other 
hypothyroid mouse genotypes (104). This impaired TSH response, however, was not 
due to a reduced number of pituitary thyrotrophs because thyrotroph cell number, as 
assessed by TSH-immunopositive cell number, was restored after chronic TRH 
treatment (105). Thus, the TRH neuron is absolutely required for both TSH and TH 
synthesis and appears to be the locus of the set-point in the HPT axis.
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Figure 1.9 Feedback regulation of thyroid hormone. Hypothalamic TRH is 
regulated by TH levels via type 2 iodothyronine deiodinase (Dio2), which 
converts T4 to a more potent T3 in tanycytes.  After increased local T3 in TRH 
neurons, T3 inhibits the prepro-TRH transcription and processing of pro-TRH into 
the mature TRH peptide through TRβ2.    
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 Moreover, hypothalamic TRH gene expression is regulated by TH levels and 
production through a negative feedback mechanism: TRH expression is high when TH 
levels are low, and TRH expression is suppressed when TH levels are increased. This 
mechanism is dependent on type II deiodinase (Dio2), which converts T4 to a more 
potent T3 in tanycytes (103).  After T3 enters TRH neurons in the paraventricular 
nucleus (PVN), regulation occurs at two levels: inhibition of expression of the prepro-
TRH transcription and processing of pro-TRH into the mature TRH peptide. The 
regulation of TRH gene expression by T3 occurs mostly through TRβ2, presumably via 
a direct mechanism (106). Another possibility is that T3 acts in the signaling pathway of 
TRH gene expression via other hypothalamic nuclei because TRβ2 is also expressed in 
the arcuate and ventromedial nuclei, and both nuclei can alter TRH expression (107). 
Leptin is one of the important regulators in hypothalamic TRH expression and 
thyroid hormones homeostasis(108). Leptin stimulates hypothalamic TRH gene 
expression via JAK2-STAT3 signaling pathway in arcuate nucleus neurons, where 
orexigenic NPY/AgRP and anorexigenic POMC signals integrate. Increased leptin levels 
cause elevated POMC signals, which in turn promotes increased TRH expression in 
PVN, while reduced leptin levels cause increased NPY/AgRP signals, which inhibits 
TRH expression. In addition, AngII increases the suppressor of cytokine signaling 
(SOCS3) through JAK2/STAT3 signaling pathway, and angiotensin II type 1 receptor 
(AT1R) is able to signal through the intracellular phosphorylation, which depends on its 
association with Janus kinases (JAKs) and signal transducer and activator of 
transcription (STAT) factors(109). The AT1R has a preferential effect on JAK2 activation 
and results in STAT3 phosphorylation (110). Several studies have shown that TRH 
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expression is directly regulated by the effect of leptin on PVN via JAK2/STAT3 signaling 
pathway. However, whether angiotensin II regulates thyroid hormones homeostasis and 
hypothalamic TRH expression through JAK2/STAT3 pathway remain uncertain.  Here, I 
investigated whether inhibition of RAS affects thyroid hormone function. 
 
RAS and erythropoiesis 
RAS regulates erythropoiesis(111), but its mechanism is not well known. Several 
studies have shown that Ang II stimulates proliferation of erythroid progenitor cells via 
AT1 receptors in vitro, whereas the inhibition of Ang II decreased burst-forming units-
erythroid (BFU-E) colony formation (112). In addition, the Ace-/- mice have severe 
anemia and administration of Ang II corrects it (113). Interestingly, anemic Ace-/- mice 
have higher plasma erythropoietin (EPO) levels than WT mice (113), although Tsukuba 
hypertensive mice (114) and patients administered with Ang II have been shown to 
increase plasma EPO levels. However, the precise mechanism of Ang II on 
erythropoiesis needs further investigation. 
 
Hypothyroidism and anemia 
Hypothyroidism is a common endocrine disorder caused by low circulating 
thyroid hormone. It usually is a primary hypothyroidism in which the thyroid gland is the 
primary site of causing this disorder. It can also be secondary or tertiary hypothyroidism 
—that is, lack of thyroid hormone secretion due to inadequate secretion of either TSH 
from the pituitary gland or TRH from the hypothalamus (115), respectively. The patient's 
presentation may vary from asymptomatic to, rarely, coma with multisystem organ 
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failure (myxedema coma). However, the common sign seen in hypothyroidism is 
anemia (116), which the red blood cells count or hemoglobin is less than normal. 
Anemia is caused by essentially through two basic pathways. One is caused by a 
decrease in production of red blood cell or hemoglobin, while another is caused by a 
loss or destruction of blood. In infants, the liver and spleen are the main organs to 
produce red blood cells, whereas bone marrow is a major place to produce red blood 
cells in adult.  Thyroid hormone has been suggested to regulate erythropoiesis in the 
bone marrow by stimulating burst-forming units-erythroid (BFU-E) colony formation (117, 
118), while EPO or the erythropoietin receptor (EPOR is not required for committing 
erythroid BFU-E and CFU-E progenitor cells(119). CD 71 is a transferrin receptor, which 
is predominately expressed in erythroid BFU-E and CFU-E progenitor cells, whereas 
ter119 erythroid marker is expressed in late stage erythroid progenitor cells (Fig 1.10). 
A number of studies have shown that thyroid hormone regulates erythropoiesis in bone 
marrow(120), and mice lacking thyroid hormone α receptor (TR α-/-) have impaired 
erythropoiesis (121). Interestingly, however, patients who have chronic kidney diseases 
(CKD) and renal transplantation who are treated with Ang I converting enzyme inhibitor 
(ACEI) (122, 123) or  Ang II type 1 blocker (ARB) have severe anemia (124), and mice 
lacking Ang I converting enzyme display decreased red blood cells, hemoglobin and 
hematocrit, whereas plasma erythropoietin was elevated (113).  Angiotensin II directly 
stimulates erythropoiesis, but Ang II indirectly stimulates erythropoiesis as well.  
However, whether thyroid hormone is responsible for mediating Ang II-induced 
erythropoiesis is not known. 
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Figure 1.10 Erythroid differentiation. CD71 is expressed in early stage erythroid 
progenitor cells, whereas ter119 is expressed in late stage erythroid progenitor cells. 
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Significance 
 The overall goal of the research demonstrated in this dissertation is to unveil the 
complexity of the RAS in leptin sensitivity, thyroid function, and erythropoiesis. Although 
the importance of RAS in the metabolic syndrome is generally acknowledged, whether 
Ang II modulates leptin sensitivity is not addressed. Understanding how renin and Ang II 
relate to fat metabolism could help in designing effective treatments of obesity and the 
metabolic syndrome.  
 In addition, patients who have chronic kidney diseases and renal transplantation 
treated with ACEI or ARBs have severe anemia, suggesting Ang II plays an important 
role in erythropoiesis. To clarify how Ang II regulates erythropoiesis, the Ren1c-/- mice 
provide important information. The results of my study provide important insight into the 
treatment of obesity with RAS inhibitors and treatment of hypothyroidism and anemia 
caused by RAS inhibition. 
  
 
 
 
Chapter 2:  
Inhibition of angiotensin II-JAK2-STAT3 pathway improves 
leptin and insulin sensitivity 
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SUMMARY 
Obesity is often associated with leptin resistance, and improving leptin sensitivity 
will be a valuable tool for treatment of obesity.  We have recently demonstrated that the 
mice lacking renin (Ren1c-/-) are lean and insulin sensitive, which is associated with 
increased energy expenditure and fecal fat excretion.  These mice have decreased 
tissue expression of suppressor of cytokine signaling 3 (SOCS3), a molecule that 
contributes to leptin resistance.  The aim of the present study is to investigate whether 
inhibiting the renin angiotensin system (RAS) improves leptin sensitivity.  An increase in 
phosphorylation of STAT3 and a decrease in AMPK activity of the hypothalamus after 
leptin administration were larger in the Ren1c-/- mice than in WT mice.  The expression 
of hypothalamic POMC was lower, and that of NPY and AgRP was higher in the Ren1c-
/- mice compared to WT mice.  These changes were recapitulated by administration of a 
type 1 Ang II receptor blocker losartan to WT mice, and Ang II reversed these changes 
whereas human renin did not.  Although a larger response to leptin of the Ren1c-/- mice 
is consistent with improved leptin sensitivity, it could simply be due to lower plasma 
leptin levels of the knockouts compared to WT as a result of lean phenotype of these 
mice.  To test this possibility I generated mice lacking both renin and leptin (Ren1c-/-
;ob/ob).  Although the Ren1c-/-;ob/ob mice have 10% lower body weight than the ob/ob 
mice, administration of leptin (100µg/kg/day for 2 weeks) decreased the % body fat 
more in the Ren1c-/-;ob/ob mice than in the ob/ob mice. A decrease in body fat of  the 
Ren1c-/-;ob/ob mice is associated with a larger decrease in food intake and food 
efficiency, a larger increase in heat generation and increased fecal fat excretion 
compared to  the ob/ob mice.  The Ren1c-/-;ob/ob mice also showed decreased 
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triglyceride content in the liver and the skeletal muscle.  The hypothalamus of the 
Ren1c-/- and the Ren1c-/-;ob/ob mice have decreased SOCS3 and phosphorylation of 
STAT3, and increased AMPK activity relative to WT or ob/ob mice. Compared to the 
ob/ob mice, the Ren1c-/-;ob/ob mice showed an increase in response to exogenous 
leptin, which  resulted in a larger changes in phosphorylation of STAT3 and AMPK 
activity with a smaller elevation of hypothalamic SOCS3 gene expression.  Changes in 
the expression of hypothalamic POMC, NPY, and AgRP after leptin administration were 
significantly larger in the Ren1c-/-; ob/ob mice than in the ob/ob mice.  The Ren1c-/-
;ob/ob mice have improved glucose tolerance, insulin tolerance and lower 
gluconeogenesis compared to the ob/ob mice.  Administration of leptin further improved 
glucose tolerance of all animals but minimized the difference between the two groups of 
mice. Improved leptin and insulin sensitivity by the absence of renin was recapitulated 
by losartan.  Together, my results demonstrate that inhibiting Ang II-AT1R pathway 
improves leptin and insulin sensitivity, and may be useful in treating insulin resistance 
and leptin resistance in human obesity and diabetes. 
  
41 
INTROUCTION 
An overactive renin-angiotensin system (RAS) induces insulin resistance and 
obesity (125, 126).  Mice  lacking renin (Ren1c-/-) are lean and insulin sensitive(102).  
Although obesity is often associated with leptin resistance (127), it is not well known 
whether inhibition of RAS improves leptin sensitivity, and whether improved leptin 
sensitivity contributes to the lean and insulin sensitive phenotype of Ren1c-/- mice. 
Leptin resistance is often induced by hyperleptinemia (127) , and low plasma leptin 
levels increase leptin sensitivity via decreased expression of the suppressor of cytokine 
signaling-3 (SOCS3), which is a negative-feedback regulator of leptin signaling JAK2-
STAT3 pathway (79).  Improving leptin sensitivity is thought to be useful for treatment of 
obesity (75); however, the target molecules for leptin sensitivity are not well identified.  
Our previous work has shown that mice lacking renin (Ren1c) have low blood pressure 
and undetectable plasma angiotensin II (Ang II). These mice are lean and insulin 
sensitive without changes in physical activity and food intake (102). Remarkably, their 
plasma leptin levels were only approximately 40% of those of wild type (WT) mice. Mice 
lacking angiotensinogen (AGT), Angiotensin converting enzyme (ACE), type 1 
Angiotensin receptor (AT1R), or type 2 Angiotensin receptor (AT2R) are also lean, and 
have low plasma leptin levels (29, 58, 126, 128). The decreased Ang II level is likely 
responsible for reduced plasma leptin levels when RAS is inhibited. Interestingly, it was 
recently shown that Ang II and leptin share the JAK2 -STAT3 signaling pathway (81, 
129-131) that regulates physiological homeostasis such as thyroid hormone levels, 
blood pressure and fluid homeostasis. Therefore, I hypothesize that inhibition of Ang II 
improves leptin sensitivity via the attenuation of leptin-JAK2-STAT3 pathway. 
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Leptin is an important hormone that regulates energy balance via JAK2-STAT3 
signaling pathway. Leptin is mainly expressed in adipose tissue and research 
hypothalamus via circulation, and binds to the leptin receptor (LRb) resulting in 
activation of  the receptor-associated tyrosine kinase JAK2, which in turn 
phosphorylates STAT3 within the LRb cytoplasmic tail (75). Through activation of JAK2-
STAT3 signaling pathway, leptin  can regulate appetite and thyroid hormone 
homeostasis, and increase energy expenditure (74). However, an overactive JAK2-
STAT3 signaling pathway causes a negative feedback inhibition. Thus, the elevated 
hypothalamic SOCS3 levels lead to leptin resistance resulting in hyperphasia, 
hyperleptinemia and accumulation of triglyceride in liver and skeletal muscle (76).  In 
contrast, mice with haploinsufficiency of SOCS3, or those with neuronal deletion of 
SOCS3 have shown to improve leptin and insulin sensitivity (77, 78). Furthermore, 
blockade of Ang II action by AT1R blockers result in decreased JAK2-STAT3 signals 
leading to in lower levels of SOCS3 expression in the hypothalamus, astrocytes, heart, 
and vascular smooth muscle (81, 129-131).  Accordingly, attenuation of leptin signaling 
by inhibition of Ang II is likely to improve leptin sensitivity. Moreover, the arcuate 
nucleus (ARC) of the hypothalamus is a critical area that senses and integrates various 
hormones and nutrient-related signaling to orexigenic and anorexigenic neurons. LRb is 
highly expressed in these neuron, which express orexigenic neuropeptide Y and Agouti-
related protein (NPY/AgRP) or anorexigenic pro-opiomelanocortin (POMC) (132). 
Phosphorylation of STAT3 by leptin also regulates expression of NPY, AgRP and 
POMC in the hypothalamus (132).  Elevated phosphorylation of STAT3 levels by leptin 
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increases the expression of  POMC, which in turn inhibits the expression of NPY/AgRP 
(133). Thus, leptin stimulates POMC neurons, and inhibits NPY/AgRP neurons resulting 
in decreased food intake and body weight (BW).  Furthermore, hypothalamic AMPK is 
an important sensor of energy balance, which is inhibited by leptin via anorexigenic 
POMC (92, 93). Stimulating AMPK by various means including adiponectin, metformin, 
and exercise has shown a great benefit in obesity and diabetes. The usefulness of 
leptin therapy in obesity, however, has not been proven because it can lead to the 
development of leptin resistance.  Thus, indentifiying signaling pathway and mechanism 
to improve leptin sensitivity is critical a potentially powerful therapeutic approach for 
treating obesity. 
Here I demonstrate that mice lacking both renin and leptin have improved leptin 
and insulin sensitivity, which leads to reduced triglyceride (TG) accumulation and 
increased fatty acid oxidation in liver and skeletal muscle. These studies directly point to 
a novel role for Ang II in leptin sensitivity and energy balance via JAK2-STAT3 signaling 
pathway.  Inhibition of Ang II combined with leptin administration provides a potentially 
powerful therapeutic approach to obesity. 
  
44 
MATERIAL AND METHODS 
Mice: The generation of Ren1c–/– mice (C57BL/6 genetic background) (20) were 
describled previously.  ob/+ mice on a C57BL/6J genetic background were purchased 
from the Jackson Laboratory (Bar Harbor, Maine) (134).  All mice were housed in 
standard cages on a 12-hour light/dark cycle, allowed free access to normal chow and 
water, and handled in accordance with the National Institutes of Health guidelines for 
the use and care of experimental animals, as approved by the IACUC of UNC-CH. 
 
Plasma leptin adiponectin measurement: Plasma levels of leptin, and adiponectin 
were determined using ELISA kits (cat number: 90040, Crystal Chem Inc. for leptin; cat 
number: K1002-1; B-Bridge International Inc. for adiponectin). 
 
MRI: Mouse body composition was evaluated using EchoMRI-100 (Echo Medical 
Systems Houston, TX) according to manufacturer’s instruction. 
 
Energy balance study using indirect calorimetry: Mice were placed in a chamber 
individually of an Oxymax system (Sophisticated Life Science Research Instrument) for 
24 hours, and readings were taken next 24 hrs after acclimation. Measurements of food 
and water intake, O2 consumption, CO2 production, and respiratory exchange ratio 
(RER) were obtained.  Data were collected and analyzed with the Oxymax Windows 
V2.3 software. Measurement and settle times were set at 60 and 120 seconds, 
respectively. 
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Liver TG measurement and plasma AST, and ALT: About 50 mg of excised frozen 
liver tissue was extracted in 1 ml of a chloroform-methanol mixture (2:1). After re-
dissolving the lipid pellet with 60 µl of tert-butanol and 40 µl of Triton X-114-methanol 
(2:1) mixture, the triglyceride was measured by triglyceride kit (cat number: 2151-015, 
StanBio) . Plasma AST and ALT were measured by automatic chemical analyzer 
(Johnson&Johnson’s VT250). 
. 
Ang II, human renin, and losartan challenge in vivo: Mice were administered Ang II 
(7.5 µg/kg/day, Sigma) or human renin (0.1µg/kg/day; cat number:  10006217, Cayman 
Chemical) with intraperitoneal i.p. Alzet miniosmotic pumps (cat number: 10190-08, 
Durect Corp., Cupertino, CA) for 2weeks.  The 3-month-old male C57BL/6 WT mice or 
ob/ob mice were fed regular chow with or without 0.45 g/l of losartan (Merck & Co., Inc.) 
in drinking water for 2 weeks (29).   
 
Oral glucose tolerance test (OGTT), insulin tolerance test (ITT), and pyruvate 
challenge test (PTT).  3-month old male mice were used by OGTT, ITT and PTT. For 
OGTT,  mice were fasted overnight and glucose was administered by gavage at a dose 
of 2 mg glucose/g BW.  At 0, 15, 30, 60, and 120 minutes after glucose administration 
blood was drawn retro-orbitally, and plasma glucose and insulin levels were measured 
by a colorimetric assay (Wako) and Ultra Sensitive Mouse Insulin ELISA kit (Crystal 
Chem Inc ), respectively.  For ITT,  mice were fasted overnight and  blood glucose level 
was measured before (0) and after 15, 30, 60, and 120 min after intraperitoneal injection 
of  insulin at a dose of 0.75 U insulin/kg BW (Eli Lily, Indianapolis, IN) (135).  For PTT, 
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mice were deprived of food for 16 hours were injected intraperitoneally with pyruvate 
dissolved in saline (2 g/kg). Blood glucose level was measured at 0, 15, 30, 60, and 120 
min. 
 
Acid Steatocrit: Acid steatocrit was measured as described previously (29).  In short, 
0.05 g of powdered specimen was mixed in 200 ml of 1 N perchloric acid.  One drop of 
0.5% oil red O was added and mixed. Specimens were placed in non-heparinized 
capillary tubes and spun. Steatocrit was calculated as 100 x length of fatty layer/(length 
of solid layer + length of fatty layer). 
 
Leptin sensitivity:  The 3-month old male mice were tested for leptin response after 2 
weeks, and 4 weeks on a normal chow. The Ren1c-/-;ob/ob and ob/ob mice were 
infused with 5µg of recombinant murine leptin (100µg/kg/day, R&D Systems, 
Minneapolis, MN) by Alzet miniosmotic pumps (cat number: 10190-08, Durect Corp., 
Cupertino, CA) for 2weeks (79).  BW, food intake and feces were measured before and 
after injection (136). 
 
Quantitative RT-PCR: mRNA levels were quantified with the Mastercycler® ep realplex 
S (Eppendorf, Westbury, NY) as described previously (29). Relative gene expression 
levels, expressed as a percentage of WT, were determined with hypoxanthine 
phosphoribosyltransferase (Hprt) as an internal standard. 
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Phospho-STAT3, AMPK activity and alpha-MSH:  For measurements of STAT3 
phosphorlaton and  isoform-specific AMPK activity, hypothalamus, liver and skeletal 
muscle tissues were lysed in ice-cold RIPA buffer (150 mM NaCl, 1% sodium 
desoxycholate, 0.1% SDS, 1% Triton X-100, and 50 mM Tris, pH 7.2) containing 1 mM 
PMSF, 5 µg/ml aprotinin, and 5µg/ml leupeptin).  STAT3 phosphorylaton was 
determined by mouse phosp-STAT3 ELISA kit (cat number: DYC4607-2, R&D systems).  
AMPK activity was measured by cyclex AMPK α activity assay kit (cat number: CY-1182, 
MBL international) (137). Alpha-MSH was measured by ELISA kit (cat number: EK-043-
01, Phoenix Pharmaceuticals, INC).  
 
Data management/Statistical analyses: All values were expressed as mean ± SEM. 
Data were analyzed by Student’s t test or analysis of variance (ANOVA). A multiple 
comparison Tukey-Kramer post-hoc test was performed to evaluate effects between 
genotypes and dietary treatment with JMP software version 8 (SAS Institute Inc., Cary, 
NC). 
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RESULTS 
Lack of Ang II decreases SOCS3 expression.   
Mice lacking renin (Ren1c-/-) are lean and insulin sensitive (102), but  we do not  
know what precise mechanism causes lean phenotype and improves insulin sensitivity 
of Ren1c-/- mice. Because leptin resistance is asscoiated with obesity and inuslin 
resistance (127), improving leptin senstivity is likely to contribute lean phenotype of the 
Ren1c-/- mice.  Because elevated SOCS3 levels lead to leptin resistance, I first 
investigated whether the lean phenotype of the Ren1c-/- mice have low expression of 
SOCS3 levels in white adipose tissue (WAT), liver, hypothalamus and skeletal muscle. I 
found that levels of SOCS3 in these tissues were 40~50% of that in WT mice (Fig. 
2.1A). Since the Ren1c-/- mice lack renin and Ang II, I next tested whether the decrease 
in SOCS3 expression is due to lack of Ang II or lack of Ang-independent effect of renin. 
When the Ren1c-/- mice were treated with a low dose of Ang II (7.5 g/kg/day), that dose 
did not affect blood pressure, but it restored SOCS3 expression to WT levels (Fig. 2.1B). 
In contrast, infusion of human renin (hRen) did not increase SOCS3 expression of the 
Ren1c-/- mice. Furthermore, WT mice treated with losartan (0.45g/l) showed a low 
expression of SOCS3 levels in the hypothalamus (Fig. 2.1B), indicating that the 
inhibition of Ang II effects decreases SOCS3 expression in the hypothalamus. 
 
Blockade of the AT1R enhances leptin response by exogenous leptin in the 
hypothalamus.  
Because SCOS3 is a negative regulator of leptin signaling pathway, decreased 
SOCS3 in the Ren1c-/- mice and WT mice treated with losartan is likely to improve 
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leptin sensitivity and enhance leptin signals by exogenous leptin. To test this I examined 
activation of JAK2-STAT3 signaling pathway and found that the hypothalamus of the 
Ren1c-/- mice and WT mice treated with losartan had lower levels of STAT3 
phosphorylation (Fig. 2.1C). In contrast, the levels of STAT3 phosphorylation were 
significantly increased in the Ren1c-/- mice and WT mice treated with losartan after 
infusion of exogenous leptin (100µg/kg/day) (Fig. 2.1C), indicating that inhibition of Ang 
II enhaced leptin signals after infusion of exogenous leptin.   
Moreover, leptin is able to regulate energy balance in the hypothalamus via 
increased expression of POMC and decreased expression of NPY and AgRP as well as 
inhibiting AMPKα activity. To investigate whether inhibition of Ang II alters energy 
balance in the hypothalamus via JAK2-STAT3 signaling pathway, I measured the 
expression of POMC, NPY and AgRP and AMPKα activity in the hypothalamus. I found 
that Ren1c-/- mice and WT mice treated with losartan had 5-fold lower POMC 
expression and 3-fold higher expression of NPY and AgRP in the hypothalamus relative 
to untreated WT mice (Figs. 2.1E-G). After Ang II (7.5 g/kg/day) infusion, the levels of 
expression of POMC, NPY and AgRP were similar to WT levels (Fig. 2.1E-G). In 
contrast, infusion of human renin did not change these gene expression levels (Fig. 
2.1E-G). In addition, both Ren1c-/- mice and WT mice treated with losartan have higher 
basal AMPKα activity and a larger decrease of AMPKα after leptin administration (Fig. 
2.1D). These data show that blockade of Ang II effects via the AT1R reduces basal 
leptin effects and enhances the response to exogenous leptin.  
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Figure 2.1 Lack of renin decreases leptin signaling pathway. A. SOCS3 expression 
levels of the white adipose tissue (WAT), liver, hypothalamus and skeletal muscle in the 
Ren1c-/- and WT mice. B. Hypothalamic SOCS3 expression in the Ren1c-/- mice, WT 
treated with losartan (0.45g/L) for 2 weeks, and Ren1c-/- mice administered with 
angiotensin II (7.5µg/kg/day) or human renin (0.1µg/kg/day) for 2 weeks. C, D. 
phospho-STAT3 levels and AMPKα activity of the hypothalamus in the Ren1c-/- mice, 
WT mice treated with losartan (0.45g/L) for one month with leptin (0.1mg/kg/day) or 
saline (control) administration. E-F. Hypothalamic neuropeptides POMC, NPY, and 
AgRP expression levels in the Ren1c-/- mice, WT mice treated with losartan and WT 
mice. All values are expressed as means ± S.E.M. n>7 *p< 0.05 vs. WT mice, and †p < 
0.05 vs. WT with leptin. Hypoth: hypothalamus, -/-: Ren1c-/- mice; ang: Ang II; hRen: 
human renin. Black bar: WT mice; white bar: Ren1c-/- mice and gray bar: WT mice 
treated with losartan. 
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Blockade of the AT1R augments anti-obesity effect of exogenous leptin.   
I have shown that blockade of the AT1R improves the response to exogenous 
leptin in the Ren1c-/- mice, but this change could simply be because the basal levels of 
leptin are low in the Ren1c-/- mice and WT mice treated with losartan. Moreover, the 
response to leptin shown above  in Fig. 2.1 was from leptin administration i.p. for 45 min. 
Therefore, I do not know whether chronic blockade of Ang II would enhance the 
response to leptin.  To investigate this, I generated mice lacking both renin and leptin 
(Ren1c-/-;ob/ob).   
Interestingly, the Ren1c-/-;ob/ob mice had lower BW than the 3-month old ob/ob 
mice (50.4 ± 1.2 g vs. 56.5 ± 1.3 g in ob/ob mice, p<0.001) (Figs 2.2A, B) and 
significantly lower body fat and lean mass (Figs 2.2C, D).  However, the ratio of  fat/BW 
did not differ (0.57 ± 0.09 vs. 0.59 ± 0.07 in ob/ob mice, p<0.5) (Fig 2.2E). 
To investigate whether blockade of the AT1R improves leptin sensitivity, I 
administered murine leptin (100µg/kg/day) to the Ren1c-/-;ob/ob mice, the ob/ob mice 
treated with losartan, and the ob/ob mice by using osmotic minipumps for 2 weeks. I  
measured food intake, BW, and body composition before and after leptin administration.  
I found that the Ren1c-/-;ob/ob mice and the ob/ob mice treated with losartan lost more 
BW compared to ob/ob mice (9.5 ± 0.5; 8.4 ± 0.6 vs. 5.1 ± 0.2 g in ob/ob mice, p<0.03), 
body fat mass, and lean mass, and obsevered decreased fat/BW ratio (Figs 2.3 A-D) 
and daily food intake relative to the ob/ob mice after leptin infusion (4.8 ± 0.5, 5.3 ± 0.3 
vs. 6.1 ± 0.8 g in ob/ob mice).  
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Fig 2. 2 Growth curve, and body composition of the Ren1c-/-;ob/ob and ob/ob 
mice. A, Growth curves of the Ren1c-/-;ob/ob and ob/ob mice from 1 to 3 months age(n 
≥10) is shown.  B. 3 month-old Ren1c-/-;ob/ob and ob/ob mice C-E. fat, lean mass and 
fat/BW by MRI in the Ren1c-/-;ob/ob and ob/ob mice. Black bar: ob/ob mice; blue bar: 
Ren1c-/-; ob/ob mice. All values are expressed as means ± S.E.M. n≥8 *p< 0.05 vs. 
ob/ob mice. 
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Figure 2.3 The Ren1c-/-; ob/ob mice lose more body weight and fat after 
administration of exogenous leptin compared to ob/ob mice. A-D. Body weight, fat 
mass, lean mass, and fat/BW before and after administration of exogenous leptin 
(100µg/kg/day) for 2 weeks. E. Plasma leptin levels after administration of exogenous 
leptin for two weeks, F,G. Fat distribution and histology of GWAT and BAT before and 
after administration of exogenous leptin for 2 weeks. All mice were 3 months old and 
values are expressed as means ± S.E.M. n ≥8 *p< 0.05 vs. ob/ob mice;  †p< 0.05 ob/ob 
mice with leptin. Black bar: ob/ob mice; blue bar: Ren1c-/-; ob/ob mice, and gray bar: 
ob/ob mice treated with losartan (0.45g/L) for one months. White adipose tissues (WAT) 
include gonada (GWAT), retroperitoneal. (RWAT), inguinal (IWAT), and brown adipose 
tissue (BAT) 
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After leptin infusion, plasma leptin levels did not differ among the three groups 
(Fig 2.3E). I also noted that Ren1c-/-;ob/ob mice had lower fat distribution in gonadal 
(GWAT), retroperitoneal. (RWAT), inguinal (IWAT) white adipose tissues, and brown 
adipose tissue (BAT), and particularly in GWAT (Figs 2.3F, G).  After leptin infusion, the 
Ren1c-/-;ob/ob mice had markedly decreased fat mass compared to ob/ob mice (Figs 
2.3F, G).  These data indicate that inhibition of Ang II improves leptin sensitivity.  
 
Mechanisms of lower BW and improved leptin sensitivity of the Ren1c-/-;ob/ob 
mice.   
There are several mechanisms including food intake, absorption, utilization and 
storage of fat, and basal metabolic rate that lead to lower body weight.  Next, I 
investigated the mechanisms of lower BW and body fat and a  larger weight loss 
response to leptin of the Ren1c-/-;ob/ob mice compared to the ob/ob mice.  Food intake 
of the Ren1c-/-;ob/ob mice was similar to that of the ob/ob mice, but their feed efficiency 
(∆BW/food intake) was lower than that of the ob/ob mice (Figs 2.4A, B, C).  Although 
the Ren1c-/-;ob/ob mice had significantly lower respiratory exchange ratio (RER) in 
comparison with ob/ob mice (Fig 2.4D), their heat generation and rectal temperature 
were indistinguishable from WT mice (Figs 2.4E, and F). Because UCP-1 is 
responsible for thermogenesis and uncouples mitochondrial electron transport from ATP 
synthesis to dissipate energy as heat, I measured the brown adipose tissue (BAT) UCP-
1 gene expression among the three groups and found that BAT UCP-1 was not different 
between Ren1c-/-;ob/ob mice and ob/ob mice without fasting (Fig 2.4G), indicating that 
heat generation is not a major contributor for lowering BW in the Ren1c-/-;ob/ob mice. 
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Inestestingly, I also found that fecal fat excretion, plasma adiopnectin and β-
hydroxybutyrate (ketone body) (Fig 2.4 H, K, and L), were higher in the Ren1c-/-;ob/ob 
mice and ob/ob mice treated with losartan compared to ob/ob mice, implicating that 
impairment of fat aborption and increased fatty acid oxidation causes lower body weight 
of the Ren1c-/-;ob/ob mice. 
After leptin infusion for 2 weeks, a decrease in food intake (4.8 ± 0.5 vs. 6.1 ± 0.8 
g in ob/ob mice) and feed efficiency, were significantly larger in the Ren1c-/-;ob/ob mice 
than that of ob/ob mice (Figs 2.4 A, B, and C).  An increase of heat generation, rectal 
temperature, and BAT UCP1 expression were larger in the Ren1c-/-;ob/ob mice, but the 
decrease of RER was similar (Figs 2.4C-G). Moreover, an increase of fecal fat 
excretion was larger in the Ren1c-/-;ob/ob mice than in ob/ob mice (13.3± 0.5 % vs. 
8.5± 0.4 %, p<0.01, Fig 2.4H), which was consistent with the expression of pancreatic 
lipase and colipase. Both enzymes were markedly decreased (Figs 2.4 I, and J). The 
effects of the Ren1c-/-;ob/ob mice on these parameters was recapitulated by ob/ob 
mice treated with losartan. These results show that inhibition of Ang II combined  with 
chronic leptin infusion increases loss of body weight due to a decrease in food intake 
and an increase in heat generation. 
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Fig 2.4 Energy balance and plasma adiponectin of the Ren1c-/-;ob/ob decreased 
food intake and increased fecal fat excretion. A, B. Daily food intake. C. feed 
efficiency. D. Respiratory exchange ratio (RER), E. Heat generation. F. Rectal 
temperature. G. BAT UCP1 gene expression. H. Fecal fat, and I, J. Expression of 
pancreatic lipase and colipase in three groups. K, L. Plasma adiponectin and β-
hydroxybutyrate levels in the ob/ob mice, Ren1c-/-;ob/ob mice, and ob/ob mice treated 
with losartan (0.45g/L) for one months with leptin infusion (100µg/kg/day) for two weeks. 
All mice at 3 months old and values are expressed as means ± S.E.M. n ≥8 *p< 0.05 vs. 
ob/ob mice, ;  †p< 0.05 ob/ob mice with leptin. Black bar: ob/ob mice; blue bar: Ren1c-/-
;ob/ob mice; grey bar: ob/ob mice treated with losartan. 
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Increased dietary fat wasting in the Ren1c-/-;ob/ob mice 
Because the expression of pancreatic lipase and colipase was lower in the 
Ren1c-/-;ob/ob mice and in the ob/ob mice treated with losartan compared to ob/ob 
mice (Fig. 2.4 I, and J), I investigated dietary fat absorption in the Ren1c-/-;ob/ob mice 
and the effect of leptin on these enzymes. Although the food intake of Ren1c-/-;ob/ob 
mice was indistinguishable from ob/ob mice, the amount of lipid in the feces was higher 
in the Ren1c-/-;ob/ob mice and leptin synergistically increased it. The estimated dietary 
fat absorption (fat calories of daily food intake - fat content from daily feces) of the 
Ren1c-/-;ob/ob mice was lower than that of ob/ob mice (6.4 ± 0.7 kcal/day In Ren1c-/-
;ob/ob mice vs. 7.8 ± 0.7 kcal/day in ob/ob mice at 3 months old, p<0.001), and leptin 
further inhibited fat absorption in all three  groups (3.5 ± 0.3 kcal/day In Ren1c-/-;ob/ob 
mice, 4.2 ± 0.3 kcal/day in ob/ob mice with losartan vs. 5.5 ± 0.4 kcal/day in ob/ob mice) 
(Figs. 2.5A-C), indicating that dietary fat wasting of Ren1c-/-;ob/ob mice most likely 
contributes to their reduced BW and fat mass.  
  
Leptin signaling and expression of neuropeptides in the hypothalamus of the 
Ren1c-/-;ob/ob mice 
  Because the expression of neuropeptides in the hypothalamus are associated 
with food intake, I next tested whether changes in leptin signals and neuropeptides  in 
the hypothalamus support the food intake data by inhibition of Ang II and by leptin.   
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Figure 2.5 Inhibition of Ang II-AT1R pathway causes increased fecal fat excretion 
and decreased total dietary fat intake and leptin further decreased fat absorption. 
A . Calorie intake from dietary fat, B. calorie loss as fecal fat, and C. intestinal uptake of 
calories from fat before and after administration of exogenous leptin (100µg/kg/day) for 
2 weeks. All mice were 3 months old and values are expressed as means ± S.E.M. n ≥8 
*p< 0.05 vs. ob/ob mice; †p< 0.05 ob/ob mice with leptin. Black bar: ob/ob mice; blue 
bar: Ren1c-/-; ob/ob mice, and gray bar: ob/ob mice treated with losartan (0.45g/L) for 
one month.  
 
 
  
59 
Similar to the Ren1c-/- mice compared to WT mice, the Ren1c-/-;ob/ob mice had lower 
SOCS3 and phosphorylated STAT3 but higher AMPK activity in the hypothalamus 
compared to the ob/ob mice (Figs. 2.6A-C). Differences in the expression levels of 
POMC, NPY and AgRP in the hypothalamus of the Ren1c-/-;ob/ob mice compared to 
the ob/ob mice are very small in comparison with that between the Ren1c-/- mice and 
WT mice (Figs. 2.6D-F, and Figs. 2.1E-G).   
After leptin infusion, the Ren1c-/-;ob/ob mice and the ob/ob mice treated with 
losartan had reduced SOCS3 levels, and enhanced increase in STAT3 phosphorlyation 
and enhanced decrease in AMPKα activity (Figs. 2.6A-C). Inhibition of Ang II effects via 
AT1R and leptin synergistically increased POMC expression and decreased expression 
of NPY and AgRP in the hypothalamus (Figs. 2.6D-F).  Because the alpha-melanocyte-
stimulating hormone (alpha-MSH) is an agonist for the melanocortin receptors and this 
peptide is processed from POMC, I also investigated that alpha-MSH level among the 
three groups and found that the Ren1c-/-;ob/ob mice and ob/ob mice treated with 
losartan had lower alpha-MSH levels compared to ob/ob mice in the hypothalamus, 
while inhibition of Ang II effect via AT1R and leptin synergistically increased alpha-MSH 
levels (Figs. 2.6G). These results suggest that inhibition of Ang II effects via AT1R 
improves leptin sensitivity in the hypothalamus and contributes to reduction of food 
intake and weight loss. 
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Figure 2.6 The Ren1c-/-;ob/ob mice show increased phospho-STAT3 and 
decreased AMPKα activity after administration of leptin. A. Hypothalamic SOCS3 
levels in 3-month old mice. B, C phospho-STAT3 and AMPKα levels in the 
hypothalamus with PBS (control) or leptin infusion (100µg/kg/day). D-F. Expression of 
neuropeptides POMC, NPY and AgRP with PBS and leptin infusion, and G. 
hypothalamic alpha-MSH levels. All values are expressed as means ± S.E.M. n=6 *p< 
0.05 vs. ob/ob mice,  and †p< 0.05 vs. ob/ob mice with leptin infusion. Black bar: ob/ob 
mice; blue bar: Ren1c-/-;ob/ob mice, and gray bar: ob/ob mice treated with losartan 
(0.45g/L) for 2 weeks. 
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Blockade of the AT1R augments anti-non-alcoholic liver disease (NAFLD) effect 
and fatty acid oxidation by exogenous leptin.  
 Since increased plasma β-hydroxybutyrate is related to fatty acid oxidation in the 
liver and skeletal muscle, I measured levels of triglycerides, fatty acid oxidation, and 
fatty acid synthesis and their relative genes expression levels  in the liver and skeletal 
muscle.  Indeed, the Ren1c-/-;ob/ob mice had lower triglyceride levels in the liver and 
skeletal muscle, and inhibition of AT1R and administration of leptin decreased liver and 
skeletal muscle triglyceride content (Figs 2.7C, D and Fig 2.8A).  I also found that 
plasma ALT and AST levels and liver weight of the Ren1c-/-; ob/ob mice were 
significantly lower than those of the ob/ob mice (ALT: 88.7 ± 14 U/L vs. 287.4 ± 54 U/L 
in ob/ob; AST: 120 ± 8 vs. 245 ± 17 U/L in ob/ob; liver weight: 1.32 ± 0.3 vs. 3.2 ± 0.5 g 
in ob/ob), and inhibition of AT1R and leptin synergistically decreased ALT and AST 
levels in the liver (Figs 2.7 A, B).  Moreover, expression of fatty acid oxidation related 
genes-PPARα, ACOX and CPT1-in liver and skeletal muscle were increased in the 
Ren1c-/-; ob/ob mice relative to the ob/ob mice (Figs 2.7 E-G and Figs 2.8 B-D). In 
contrast, expression of fatty acid synthesis related genes- fatty acid synthase (FAS) and 
glycerol-3-phosphate acyltransferase (GPAT1)- were markedly decreased in the Ren1c-
/-; ob/ob mice relative to the ob/ob mice (Figs 2.7 H, I and Figs 2.8 E, F). This finding 
indicates that increased fatty acid oxidation in the liver and skeletal muscle of the 
Ren1c-/-; ob/ob mice results in increased plasma ketonbodies, which is consistent with 
reduced RER. I conclude that inhibition of AT1R and administration of leptin increased 
fatty acid oxidation in the liver and skeletal muscle, and could contribute to fat utilization 
in the Ren1c-/-; ob/ob mice.  
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Figure 2.7 Inhibition of Ang II effects protects against non-alcoholic liver disease 
and enhance fatty acid oxidation. A, B. Liver function (AST and ALT) in the ob/ob 
mice, Ren1c-/-;ob/ob mice, and ob/ob mice treated with losartan. C. Liver histology of 
the ob/ob mice, Ren1c-/-;ob/ob mice, and ob/ob mice treated with losartan. D. Liver 
triglyceride contents of the ob/ob mice, Ren1c-/-; ob/ob mice, and ob/ob mice treated 
with losartan with PBS (control) or leptin (100µg/kg/day) for 2 weeks. E-G mRNA levels 
of liver PPARα,  acyl-coenzyme A oxidase 1 (ACOX1), and carnitine 
palmitoyltransferase I (CPT1). H,I. mRNA levels of fatty acid synthase (FAS) and 
glycerol-3-phosphate acyltransferase (GPAT1).  Data were obtained from 3-month-old 
male mice. All values are expressed as means ± S.E.M. n=7 *p< 0.05 vs. ob/ob mice; 
†p< 0.05 ob/ob mice with leptin. Black bar: ob/ob mice; blue bar: Ren1c-/-;ob/ob mice, 
gray bar: ob/ob mice treated with losartan(0.45g/L) for one month. 
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Figure 2.8 Inhibition of Ang II effects causes increased fatty acid oxidation related 
gene expression in skeletal muscle. A. skeletal muscle triglyceride content of the 
ob/ob mice, Ren1c-/-; ob/ob mice, and ob/ob mice treated with losartan with PBS 
(control) or leptin (100µg/kg/day) for 2 weeks. B-D skeletal muscle PPARα, acyl-
coenzyme A oxidase 1 (ACOX1), and carnitine palmitoyltransferase I (CPT1) mRNA 
levels and E, F. fatty acid synthase (FAS) and glycerol-3-phosphate acyltransferase 
(GPAT1) at 3-month old male mice. All values are expressed as means ± S.E.M. n=7 
*p< 0.05 vs. ob/ob mice; †p< 0.05 ob/ob mice with leptin. Black bar: ob/ob mice; blue bar: 
Ren1c-/-;ob/ob mice, gray bar: ob/ob mice treated with losartan(0.45g/L) for one month.  
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Inhibition of Ang II in ob/ob mice improves insulin sensitivity. 
Leptin and AT1R inhibition improve insulin sensitivity (125).  I next investigated 
whether improved insulin sensitivity by inhibition of RAS is independent of leptin or is 
due to improved leptin sensitivity. The Ren1c-/-;ob/ob mice and the ob/ob mice with 
losartan treatment had lower plasma level of glucose and insulin (Figs 2.9 A, B), and 
improved glucose tolerance and insulin tolerance compared to the ob/ob mice (Figs 2.9 
C-E).  They also had reduced gluconeogenesis evaluated by pyruvate tolerance test 
(Figs 2.9 F ), which is consistent with reduced expression levels of 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6P) in the 
liver (Figs 2.9 G, and H).  After leptin infusion for 2 weeks, all groups had improved 
glucose, insulin and pyruvate tolerance, but the difference between the Ren1c-/-;ob/ob 
mice and the ob/ob mice became smaller as compared to before leptin infusion (Figs 
2.9 C-F).  
Because adiponectin has demonstrated improved insulin sensitivity and plasma 
adiponectin levels of the Ren1c-/-; ob/ob mice were three times higher than those of the 
ob/ob mice (Figs 2.4 K) when leptin did not further plasma adiponectin levels of the 
Ren1c-/-; ob/ob mice, but it increased them in the ob/ob mice and the ob/ob mice 
treated with losartan, and the plasma levels of adiponectin became similar among the 
three groups of mice (Fig 2.4K).  Accordingly, the adiponectin results are consistent 
with the glucose and insulin tolerance after leptin infusion.   
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Figure 2.9 Inhibition of Ang II Improves glucose tolerance and insulin tolerance. A, 
B. Plasma glucose and insulin levels. C, D. Oral glucose tolerance test (OGTT) for the 
ob/ob mice, Ren1c-/-; ob/ob mice, and ob/ob mice treated with losartan with PBS 
(control) or leptin (100µg/kg/day) for 2 weeks. E. Insulin-tolerance test (ITT) for the 
ob/ob mice, Ren1c-/-; ob/ob mice, and ob/ob mice treated with losartan with PBS 
(control) or leptin (100µg/kg/day) for 2 weeks). F. pyruvate challenge test (PTT) for the 
ob/ob mice, Ren1c-/-; ob/ob mice, and ob/ob mice treated with losartan with PBS 
(control) or leptin (100µg/kg/day) for 2 weeks, and G, H. liver gluconeogenesis gene 
expression, PEPCK and G-6P. All mice at 3 months old and values are expressed as 
means ± S.E.M. n ≥8 *p< 0.05 vs. ob/ob mice. Black bar: ob/ob mice; blue bar: Ren1c-/-; 
ob/ob mice, and gray bar: ob/ob mice treated with losartan (0.45g/L) for one month. 
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I conclude that inhibition of Ang II effects or leptin infusion improves glucose 
tolerance and insulin sensitivity possibly due to increased plasma adiponectin (Fig 2.10). 
 
 
 
 
Figure 2.10 Proposed mechanism of how inhibition of Ang II effects improves 
leptin and insulin sensitivities and enhances fatty acid oxidation. 
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DISCUSSIONS 
In this study I have demonstrated that inhibiting Ang II improves leptin and insulin 
sensitivity.  Previously we reported that food intake (g/mouse/day) of the Ren1c-/- mice 
was similar to that of WT mice (29).  Because the body weight of the Ren1c-/- mice was 
smaller than that of WT mice, when food intake is expressed as food intake (g)/body 
weight (g)/day, the values of the Ren1c-/- mice were larger than those of WT mice (0.15 
± 0.01 g/body weight/day vs. 0.09 ± 0.01 g/body weight/day in WT, p<0.01), showing 
that absence of renin increases food intake. Therefore the lean phenotype of the 
Ren1c-/- mice is due to some mechanisms that overcome the increase in food intake. 
Absence of renin decreased plasma leptin levels(102), which is consistent with 
reduced SOCS3 expression and STAT3 phosphorylation, and increased AMPK activity 
in the hypothalamus as well as decreased expression of POMC, increased expression 
of NPY and AgRP in the hypothalamus (Figs. 2.1 A-G).  AMPK works as an energy 
gauge in the hypothalamus and a number of factors including adiponectin, insulin, 
glucose and leptin levels are involved in regulating hypothalamic AMPK activity(95).  
Increased AMPKα activity in the Ren1c-/- mice is probably due to reduced plasma 
insulin and leptin concentrations together with increased plasma adiponectin levels. 
Intracerebroventricular administration of insulin and leptin inhibits hypothalamic AMPK 
activity and food intake (138). Changes in the expression of these neuropeptides are 
consistent with increased food intake (g/body weight/day) of the Ren1c-/- mice 
compared to WT mice, and are due to lack of Ang II, and not to a decrease in renin per 
se, because hypothalamic expression of POMC, NPY, and AgRP in the Ren1c-/-;ob/ob 
mice was similar to that of the ob/ob mice treated with losartan (Figs. 2.6 D-F). 
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The Ren1c-/-;ob/ob mice had lower body fat and weight than the ob/ob mice.  
However, because the Ren1c-/-;ob/ob mice also had reduced lean body mass, they had 
fat/BW similar to that of the ob/ob mice (Figs. 2.2 A-E). The food intake of the Ren1c-/-
;ob/ob mice (g/body weight/day) was similar to that of the ob/ob mice, and the heat 
generation of the Ren1c-/-;ob/ob mice did not differ from the ob/ob mice.  Absence of 
the difference in food intake is consistent with similar levels of expression of POMC, 
NPY, and AgRP between the Ren1c-/-;ob/ob mice and the ob/ob mice (Figs. 2. 6 D-F).  
Accordingly, lower body weight of the Ren1c-/-;ob/ob mice relative to ob/ob mice is 
mainly due to an increased fecal fat loss, which is likely due to reduced pancreatic 
lipase and colipase in the absence of renin as we previously demonstrated (Figs. 2.4 H-
J)(29). 
After leptin infusion, the Ren1c-/-;ob/ob mice and the ob/ob mice treated with 
losartan had a larger anti-obesity and anti-non-alcoholic steatohepatitis effect than 
ob/ob mice, demonstrating improved leptin sensitivity when RAS is inhibited. These 
effects are likely the results of a combination of reduction in food intake, increase in 
heat generation, fecal fat excretion and fatty acid oxidation (Figs. 2.4 A, E, H and L). 
Suppression by exogenous leptin of food intake of the Ren1c-/-; ob/ob mice and of the 
ob/ob mice treated with losartan is probably due to increased levels of hypothalamic 
POMC expression. Indeed, mice lacking SOCS3 in POMC expressing cells have 
increased leptin sensitivity and decreased BW and food intake due to elevated levels of 
hypothalamic POMC expression in the hypothalamus (79). Delivery of POMC peptide 
into the hypothalamus of obese Zucker (fa/fa) rats increased energy expenditure and 
augmented thermogenesis in brown adipose tissue (139), whereas POMC null mice 
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have decreased energy expenditure (140). In addition, leptin increases energy 
expenditure and thermogenesis by activating the sympathetic nervous system 
(SNS)(141), and by increasing thyroid hormone synthesis via increasing TRH through 
activating JAK2-STAT3 pathway. 
The Ren1c-/-;ob/ob mice had increased fecal fat excretion relative to the ob/ob 
mice. Interestingly, leptin infusion markedly increased fecal fat excretion in the Ren1c-/-
;ob/ob mice (Fig. 2.4 H).  This result is consistent with the finding that leptin directly 
inhibited both secretion and intracellular activity of pancreatic lipase(142).  Because the 
Ren1c-/-;ob/ob mice had only 25% expression of pancreatic lipase and colipase as WT 
mice (Figs. 2.4 I, and J), administration of leptin further decreased pancreatic lipase, 
leading to more fecal fat loss and smaller BW change. 
Compared to WT and ob/ob mice the Ren1c-/- mice and the Ren1c-/-;ob/ob mice 
have lower plasma glucose concentrations and insulin levels by OGTT, have a larger 
decrease in plasma glucose levels by ITT, and their gluconeogenesis was less by PTT 
(Figs. 2.9 A-F).  Increased plasma adiponectin likely contributes to these results 
because adiponectin improves insulin sensitivity (Fig. 2.4 K)(143), and because Ang II 
decreases adiponectin production in 3T3-L1 adipocytes and losartan inhibits it (Li et al., 
our unpublished observation).  Treatment of WT mice and the ob/ob mice with losartan 
have significantly increased plasma adiponectin concentrations, and they had improved 
glucose tolerance and insulin sensitivity, and had reduced gluconeogenesis similar to 
those of the Ren1c-/- mice and the Ren1c-/-;ob/ob mice (Figs. 2.9 G, and H), indicating 
the contribution of Ang II-dependent mechanism(s).  Interestingly, chronic leptin 
administration improved insulin sensitivity in the ob/ob mice, but not in the Ren1c-/-
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;ob/ob mice and the ob/ob mice treated with losartan (Figs. 2.9 C- E).  This may be 
because chronic leptin administration increased plasma adiponectin levels in the ob/ob 
mice, but not in the Ren1c-/-;ob/ob mice and the ob/ob mice treated with losartan, 
simply because adiponectin production reached maximum levels by inhibiting RAS, and 
further stimulation by leptin did not increase adiponectin any more (Fig. 2.4 K). 
In summary, I have shown that inhibition of RAS improves leptin sensitivity and 
insulin sensitivity, and augments anti-obesity and anti-diabetic effects of leptin.  
Inhibition of RAS increased fecal fat excretion and fatty acid oxidation independently of 
leptin (Figs. 2.10). Inhibition of Ang II effects may provide a novel molecular approach 
for treatment of obesity. 
 
  
 
 
 
 
Chapter 3: Absence of angiotensin II causes anemia due to 
tertiary hypothyroidism 
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SUMMARY 
Inhibiting the renin angiotensin system (RAS) causes anemia.  However, its 
mechanism is not fully understood.  Here we provide evidence that inhibiting 
angiotensin II (Ang II) effects via its type 1 receptor causes tertiary hypothyroidism by 
directly decreasing TRH and by feedback inhibition of TRH by increased hypothalamic 
iodothyronine deiodinase Dio2 and thus T3 in the hypothalamus.  Moreover, inhibiting 
RAS in mice causes severe normochromic, normocytic anemia with normal reticulocyte 
index and elevated erythropoietin, which is corrected by administration of Ang II or T3.  
However, Ang II did not correct anemia in wild type mice that were made hypothyroid by 
methimazole. Interestingly, Ren1c-/- mice treated with high dose erythropoietin did not 
correct their anemia. In contrast, inhibiting RAS caused markedly decreased BFU-E and 
CFU-E colonies, which was corrected by thyroid hormone.  I conclude that 
hypothyroidism is the predominant cause of anemia caused by inhibiting RAS. 
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INTROUCTION 
As discussed in chapter 2, JAK2-STAT3 signaling pathway plays an important 
role in leptin sensitivity. Because Ren1c-/- mice and inhibition of RAS by losartan or 
enalapril cause decreased phosphorylation of STAT3, which is associated with reduced 
expression of TRH in the hypothalamus and results in hypothyroidism, I investigated the 
role and mechanism of Ang II on the thyroid hormone pathway in the chapter 3.  Mice 
lacking renin (Ren1c) have low BP, are lean, and have increased energy expenditure 
and improved insulin sensitivity (102). Given that their increased energy expenditure is 
associated with elevated thermogenesis, we expected an activation of sympathetic 
nervous system and/or an increase in thyroid hormones.  However, plasma 
norepinephrine concentration and norepinephrine production in brown adipose tissue of 
the Ren1c-/- mice are similar to those of WT mice (29).  Surprisingly, plasma levels of 
total T3 and T4 were approximately 50% of those of WT mice(29).  However, we were 
not able to find clear clinical findings in the Ren1c-/- mice that were consistent with 
hypothyroidism such as growth inhibition (shorter body length), lower rectal temperature, 
and a decrease in α-myosin, and an increase in-myosin heavy chain (MHC) 
expression in the heart.  The histology of the thyroid gland was also indistinguishable 
between the Ren1c-/- and WT mice.  Although thyroid hormones activate RAS (144, 
145), whether RAS conversely affect thyroid hormones is not known. Reduced total T3 
and T4 might simply reflect the reduced thyroid hormones bound to thyroxine binding 
globulin (TBG) and might not necessarily mean that free active forms of thyroid 
hormones in the plasma of the Ren1c-/- mice are decreased.   
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If an inhibition of RAS really causes hypothyroidism, the cause of hypothyroidism 
could be low TRH, low TSH, and/or low thyroid hormone synthesis itself.  When renin or 
(pro)renin bind to a recently found (pro)renin receptor, they activate MAP kinases 
independently of Ang II (30).  Thus it is possible that hypothyroidism in the Ren1c-/- 
mice is mediated either by the absence of Ang II or by lack of Ang II-independent direct 
effect of renin to activate MAP kinases.  Accordingly, in the first half of this study I tested 
whether and how inhibiting RAS causes hypothyroidism. 
It is well established that inhibiting RAS causes anemia.  A number of clinical 
reports have shown that RAS is associated with erythropoiesis(146, 147).  Patients with 
chronic kidney diseases treated with Ang converting enzyme (ACE) inhibitors (122, 123) 
or angiotensin receptor blockers (ARB) develop severe anemia (124), which is 
consistent with severe anemia in mice lacking ACE (113).  The Ace-/- mice have 
decreased red blood cell number, hemoglobin (Hgb) and hematocrit (Hct) (113).  
Administration of Ang II to Ace-/- mice corrected anemia (113).  However, the 
mechanisms of how decreased Ang II effects causes anemia is not well known.  
Moreover, several studies have demonstrated that administration of Ang II stimulates 
proliferation of erythroid progenitor cells in vitro (112) and increases erythropoietin (EPO) 
levels (122, 148), a potent humoral stimulator of erythropoiesis. In addition, Tsukuba 
hypertensive mice that harbor both human renin transgene and human angiotensinogen 
transgene have high BP and erythrocytosis (114).  Interestingly, transplanting bone 
marrow of AT1aR-/- mice to Tsukuba hypertensive mice did not correct erythrocytosis, 
showing that AT1aR is dispensable for erythropoiesis in the bone marrow (114).  This 
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study suggests indirect effect(s) of Ang II mediate erythropoiesis.  However, the 
mechanism of how RAS affects erythropoiesis is not fully understood. 
Moreover, anemia is often seen in patients who have hypothyroidism (149). Mice 
lacking thyroid hormone receptor α (TR α-/-) are anemic due to impaired erythropoiesis 
in the bone marrow (120, 121).  Because thyroid hormone is an important regulator of 
erythropoiesis in the bone marrow by stimulating burst-forming units-erythroid (BFU-E) 
colony formation (117, 118), in the second half of this study I tested the hypothesis that 
inhibition of RAS causes anemia through inhibiting thyroid hormone pathway. My data 
demonstrate that inhibiting RAS causes tertiary hypothyroidism, and that 
hypothyroidism is the primary cause of anemia induced by inhibiting RAS. 
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MATERIAL AND METHODS 
Mice: Three to four-month-old male WT and Ren1c-/- mice(20) on C57BL/6 genetic 
background were housed in standard cages on a 12-hour light/dark cycle, allowed free 
access to normal chow and water, and handled in accordance with the National 
Institutes of Health guidelines for the use and care of experimental animals, as 
approved by the IACUC of UNC-CH. 
 
Histology of thyroid gland: Thyroid glands were removed from mice and put on 4% 
paraformaldehyde (PFA) for 24 hours and sent them to UNC histology core facility. 
 
Rectal temperature: Rectal temperature of mice was measured using a precalibrated 
thermistor probe YSI 4600 (Yellow Springs Instrument Co., Yellow Springs, Ohio, USA). 
Mice were fasting for 4 hours first and then exposure at 4 °C for 2 hours to measure 
rectal temperature every 30 minutes.   
 
BP: BP was measured using a computerized tail-cuff method(150). 
 
Measurement of hypothalamic T3 and plasma free T3 and free T4 and alpha-MSH: 
HypothalamicT3 was extracted from the hypothalamus by adding methanol 95% 
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containing PTU 10−4 M. Tissues were homogenized and centrifuged at 13 000 rpm and 
the pellets re-suspended twice using methanol solution. The supernatants were 
evaporated to dryness and resuspended in GAB buffer (0.2 M glycine/0.13 M acetate 
with 0.02% BSA). T3 was determined by radioimmunoassay system (RIA). Samples 
and standard curve were incubated at 4 °C with poly clonal antibody against T3 
(Fitzgerald Industries International, Concord, MA) in RIA buffer GAB. Three days later, 
10 000 cpm of radiolabeled 125I T3 (Specific activity 2200 Ci/mmol; Perkin–Elmer Life 
Sciences, Boston MA) was added to each tube. After two days of incubation, a rabbit 
gamma globulin (Jackson ImmunoResearch Laboratories) diluted in 0.1 M EDTA and 
16% polyethylene glycol with goat ant-rabbit IgG (Antibodies Incorporated, Davis CA) in 
GA buffer (0.2 M glycine/0.13 M acetate) was added to precipitate the antibody–T3 
complex. After centrifugation the precipitates were counted in a γ-counter. T3 is 
expressed in picogram per milligram of weight tissue. Plasma free T3 and T4 levels 
were measured with ELISA kit (catalog number: 25-FT3HU-E01, and 25-FT4HU-E01; 
ALPCO).  TSH was measured with ELISA kit (catalog number: SY45201, IBL 
International GmbH). Hypothalamic α-MSH was measured by mouse α-MSH EIA kit 
(catalog number: EK-043-01, Phoenix Pharmaceuticals, Inc.). 
 
 
pSTAT3: STAT3 phosphorylation levels in hypothalamus were measured by ELISA kit 
(Catalog Number KCB4607 R&D Systems). The results were repeated by western blot 
method.    
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Administration of angiotensin II, human renin, human EPO, thyroid hormone, 
losartan, enalapril, and methimazole challenge in vivo:  Losartan (Merck & Co., Inc.) 
0.45 g/l or enalapril (Sigma) 0.3g/l or methimazole (Sigma) 2g/l were given in the 
drinking water for 2 months.  Angiotensin II (7.5 µg//kg/day), human renin (0.1µg/kg/day) 
or human EPO (5000IU/kg/ three times/per week, Cell Science) or triiodothyronine T3 
(5µg/kg/day, or 300ng/kg/day) were administered i.p. using osmotic minipumps (Durect 
Corp) for 2weeks. 
 
N1 Cell Culture: Mouse hypothalamic cell line (N1 cells) was from Cellutions 
Biosystems Company. Cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum in 5% CO2.  Serum was deprived 
for 24 hrs before testing the effects of Ang II or human renin.   
 
Hypothalamic tanycytes primary cell culture.  Primary cultures were established 
from mice fetal day 17 hypothalamus as described (151).  In brief, pregnant females 
were anaesthetized with isoflurane, the embryos removed individually, and the 
hypothalamus was excised under a stereoscopic microscope and placed in Hank's 
solution.  After the removal of embryos, pregnant females were killed under anesthesia. 
Tissues were enzymatically dissociated with trypsin (Sigma, Missouri, USA). Cells were 
plated on dishes coated with 1.5 mg/mL poly D-lysine (Sigma) for RT-PCR. The 
medium used was Dulbecco’s Modified Eagle Medium (DMEM) supplemented with fetal 
bovine serum (10%), vitamins, glucose, glutamine and insulin. The losartan (10 nmol/L) 
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and AG-490 (10 nmol/L) were added to cell medium for 24 hrs for measuring TRH 
mRNA (152).  
 
Dio2 activity Dio2 activity was measured as previously described (153, 154) by the 
release of 125I from 2 nM [125I] T4 (NEN Life Science Products Inc., Boston) in the 
presence of 20 mM DTT and 1 mM PTU in dissected tissues.  All activity values were 
corrected by protein concentration in each sample. 
 
Hematological indices:  Total blood of 20µl were drawn for determination of RBC 
number, hemoglobin, hematocrit, mean corpuscular volume (MCV), and mean 
corpuscular hemoglobin (MCH).  All analyses were performed by Heska Veterinary CBC 
DIFF machine (Heska).   
 
Reticulocyte stain and reticulocyte index: Blood and reticulocyte staining solution, 
New Methylene Blue (sigma), were mixed together for 5 minutes and marked blood 
smear for counting reticulocyte number under light microscope 1000x magnificent. 
Ribosomal RNA is precipitated by the cationic dye. Corrected reticulocyte count index 
was determined by reticulocyte % x corrected factor/ RBC volume. Corrected factor is 
dependent on HCT levels. HCT: 40-45% is 1, 35-39 is 1.5 and 25-34% is 2.  
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Plasma volume, blood volume, and red blood cell volume 
Plasma volume (PV) was determined by Evans blue dye dilution. As previously 
described (155), 20 µl of 0.4% solution of Evans blue dye (sigma) injected into tail vein. 
Blood samples (l0 µl) were collected every 10 minutes until 30 minutes after injection. 
Plasma was diluted 1:100 in water and Evans blue dye was used as standard to 
measured concentration at 620 nm. Extrapolation of the regression line to 0 to 30 
minutes, and allowed 0 minute as total injection concentration. Blood volume (BV) is 
estimated by PV divided by 1-HCT, red blood cell volume is BV-PV.     
 
Plasma EPO:  5 µl of blood were drawn and collected on ice in tubes.  Plasma was 
frozen immediately after blood collection and stored at -80ºC until were performed.  
EPO was measured using a ELISA kit (R& D systems). 
 
Bone marrow: mice bone marrow suspensions were from the femurs.  After removing 
femurs, using No.18 needle flashed femur and collected bone marrow cells in DMEM 
medium.  Adjust the cell density of each suspension to 1 × 106cells/ml for flow cytometry. 
 
Fluorescence-activated cell sorting (FACS): Single cell suspensions obtained from 
the bone marrow were labeled with antibodies PE-TER119, and FITC-CD71 
(Pharmingen, San Diego) for 30 min. Cells were analyzed on Cytek FACS machine 
(Becton Dickinson) using Summit software. For CD71 and TER119 percentages were 
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dependent on markers intensity of FACS results multiple with bone marrow cells 
number and then divided by WT mice. Total FACS cells were 150,000 cells/each 
sample.  
 
CFU-E and BFU-E colony assay: For evaluation of burst-forming unit erythroid (BFU-E) 
and colony-forming unit erythroid (CFU-E), bone marrow cells were seeded at various 
concentrations (1×105 cells/well) into semisolid medium MethoCultM334 (Stem Cell 
Technologies) in 12 well dishes.  For evaluation of CFU-Es, small compact colonies 
were counted 48 hours later, and for BFU-Es 6 days later. The cells stained for the 
presence of hemoglobin with benzidine, and counted with brown color positive cells. 
 
RNA analysis: Total RNA was extracted from brain tissues by a monophasic solution of 
phenol and guanidine isothiocyanate (TRIzol Reagent, Life Technologies, Invitrogen, 
Carlsbad, California, USA) (20).   mRNA levels were quantified with the Mastercycler® 
ep realplex S (Eppendorf, Westbury, NY) (29).  Relative gene expression levels were 
determined with hypoxanthine phosphoribosyltransferase (Hprt) as an internal standard, 
and expressed as a percentage of WT.  
 
Data management/Statistical analyses: All values were expressed as mean ± SEM. 
Data were analyzed by Student’s t test or analysis of variance (ANOVA).  Tukey-Klamer 
post-hoc test was performed with JMP software version 8 (SAS Institute Inc., Cary, NC).
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RESULTS 
The Ren1c-/- mice have tertiary hypothyroidism. 
Because reduced total T3 and T4 in the Ren1c-/- mice might simply reflect the 
reduced thyroid hormones bound to thyroxine binding globulin (TBG) and might not 
necessarily mean hypothyroidism, I first measured free forms of thyroid hormones in the 
plasma of the Ren1c-/- mice. The Ren1c-/- mice showed reduced levels of free T3 and 
T4 compared with WT (fT3: 1.3 ± 0.2 pg/ml vs. 2.2 ± 0.2 pg/ml, p< 0.01; fT4: 0.4 ± 0.02 
ng/dl vs. 1.1 ± 0.04 ng/dl , p< 0.01) (Figs. 3.1A,and B; Table 3.1). Plasma TSH and 
gene expression of TRH in the hypothalamus of the Ren1c-/- mice were also 
approximately half of WT mice (Figs. 3.1C, and D).  Decreased fT3, fT4, TSH, and TRH 
were all recapitulated by administering WT mice with an ARB losartan or an ACE 
inhibitor enalapril (Figs. 3.1A-D), indicating that inhibition of Ang II effects via AT1R 
decreases circulating thyroid hormone.  
Core body temperature decreases in hypothyroidism. However, the basal rectal 
temperature was indistinguishable between the Ren1c-/- and WT mice when we 
measured it without fasting the animals (not shown).  Interestingly, after 4 hrs of fasting, 
it was lower in the Ren1c-/- mice compared to WT mice, although it did not reach 
statistical significance.  When the animals were then kept at 4°C, the rectal temperature 
of the Ren1c-/- mice decreased rapidly compared to WT mice (Fig. 3.1E). Cold 
intolerance of the Ren1c-/- mice was also recapitulated by WT mice treated with 
losartan or enalapril (Fig. 3.1E).  
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Figure 3.1 The effects of inhibition of renin angiotensin system on fT3, fT4, TSH, 
and TRH and cold tolerance. A, B. plasma free thyroid hormones (fT3 and fT4), C. 
TSH levels, and D. hypothalamic TRH expression levels. E. Rectal tempature after cold 
exposure (4°C) of the Ren1c-/- mice, WT mice and mice treated with losatan(0.45g/L 
drinking water) or enalarpil (0.3g/L drinking water) for two weeks. F. Rectal tempature 
after cold exposure of the same groups of mice as show E. treated with these mice 
treated with thyroid hormone (T3, 5µg/kg/day) for two weeks.  All values are expressed 
as means ± S.E.M. n ≥8 *p< 0.05 vs. WT mice.  
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Reduction in rectal temperature of the Ren1c-/- mice was restored by administration of 
thyroid hormone (T3; 5µg/kg i.p.) using osmotic minipumps for 2 weeks (37.9 ± 0.7°C vs. 
37.8°C ± 0.5 in WT) ( Fig 3.1F). 
To determine whether low levels of thyroid hormones and TSH are caused by 
reduced TRH, I administered TRH (5.0 µg/kg, i.p.) into the Ren1c-/- mice, which 
restored their thyroid hormones and TSH to the levels of WT (Figs. 3.2A-C).  
Hypothyroidism recapitulated by an ARB or an ACE inhibitor was corrected by 
administering TRH (Figs. 3.2A-C).  I conclude that inhibition of Ang II effects via AT1R 
causes tertiary hypothyroidism,  
 
Ang II corrects hypothyroidism of the Ren1c-/- mice by directly increasing TRH 
via AT1R-JAK-STAT pathway. 
I next asked relative contribution of Ang II and Ang-independent effect of renin on 
tertiary hypothyroidism of the Ren1c-/- mice.  Given that human renin does not cleave 
mouse angiotensinogen to produce Ang I (156), but both human and mouse renin are 
capable of activating MAPK in mouse cells, I took advantage of this property and 
administered human renin to the Ren1c-/- mice to investigate the Ang-independent 
effects of renin.  Ang II but not human renin restored TRH, TSH, and fT3 to the WT 
levels (Figs. 3.3A-D), demonstrating that Ang II but not renin per se stimulates 
hypothalamic-pituitary-thyroid axis.   
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Figure 3.2 TRH corrects teritary hypothyroidism. A. plasma free T3, B. 
plasma free T4. C. plasma TSH levels. All values are expressed as means ± 
S.E.M. n ≥8 *p< 0.05 vs. WT mice. -/-: Ren1c-/- , LOS: WT mice treated with 
losartan(0.45g/L drinking water) for 4 weeks  or ENA, WT mice treated with 
enalapril (0.3g/L drinking water) for 4 weeks.†p< 0.05 vs. without treating TRH.    
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Figure 3.3 Reduced Ang II causes tertiary hypothyroidism and Ang II corrects it 
via AT1R. A-D Ang II effect and renin effect on plasma free T3, T4 and TSH and 
hypothalamic TRH gene expression. E. Ang II effect on blood pressure. F. STAT3 
phosphorylation levels in the hypothalamus. G. Ang II effect in N1 cells. H. Ang II 
increases hypothalamic TRH via Ang II type1 receptor and Jak2. All values are 
expressed as means ± S.E.M. n ≥8 *p < 0.05 vs. WT mice or N1 cell without treatment. 
Ang II: angiotensin II(7.5µg/kg/day) for 2 weeks, and hREN:human renin (0.1µg/kg/day) 
for 2 weeks.  -/-: Ren1c-/- mice, LOS: WT mice treated with losartan (0.45/L in drinking 
water) or N1 cells treated with losartan (10 nmol/L), AG: N1 cells treated with AG490 
(10 nmol/L), and PD: N1 cells treated with PD123319 (10 nmol/L).  
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 It is known that AT1R activates JAK2 and phosphorylates STAT3 (110, 157), and 
leptin increases hypothalamic TRH expression via JAK2-STAT3 pathway (158).  
Phosphorylated STAT3 binds to TRH promoter and increases its expression (83, 158). 
Consistent with this previous finding, hypothalamic phosphorylated STAT3 levels of  the 
Ren1c-/- mice and of  WT mice treated with losartan were significantly lower than those 
of WT control mice (Fig. 3.3F), which supports the idea that Ang II increases 
hypothalamic TRH expression by activating JAK-STAT3 pathway. In addition, the 
Ren1c-/- mice have 40% WT levels of leptin, which is comparable to that of 
heterozygous leptin deficient mice.  However, TRH, TSH and free forms of thyroid 
hormones of heterozygous leptin deficient ob/+ mice did not differ from those of WT 
mice (Figs. 3.4 A, B), indicating reduced leptin in the Ren1c-/- mice does not contribute 
to hypothyroidism of these mice.   
The Ren1c-/- mice, WT mice with losartan or enalapril all have similar levels of 
low BP, which might contribute to hypothyroidism.  However a calcium channel blocker 
amlodipine, or an inhibitor of NaK2Cl cotransporter, furosemide, that decrease BP to the 
levels of the Ren1c-/- mice did not affect fT3 and fT4 (Figs 3.4C-E), showing that 
hypotension of the Ren1c-/- mice does not alter the hypothalamic-pituitary-thyroid axis.  
To test whether Ang II directly increases TRH, I treated mouse hypothalamic neuronal 
cell line N1 with Ang II (10-11, 10-9, and 10-7 M).  Ang II increased TRH gene expression 
in N1 cells (Fig. 3.3G), which was abolished by an AT1R antagonist losartan, but not by 
an AT2R antagonist PD123319 (Fig. 3.3H), showing that Ang II increases TRH by 
activating AT1R.  Consistent with in vivo data (Fig.3.3.F) a JAK/STAT3 inhibitor (151), 
AG490 abolished the increase in TRH by Ang II (Fig. 3.3H).   
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Figure3.4 Hypothyroidism is not due to reduction in blood pressure. A, B. 
thyroid hormones (free T3 and T4) in ob+/- and ob/ob mice C-E. Tail cuff blood 
pressure and thyroid hormones (free T3 and T4) in WT mice treated with 
amlodipine (0.1µg/L) and furosemide (0.1µg/L) for 2 weeks. All values are 
expressed as means ± S.E.M. n=7 *p< 0.05 vs. WT mice.  
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I conclude that reduced activation of AT1R causes tertiary hypothyroidism by directly 
decreasing TRH expression in the hypothalamus via JAK2-STAT3 pathway.    
 
Inhibition of RAS-AT1R directly increases Dio2, which increases hypothalamic T3 
and decreases TRH. 
Another possible mechanism of inhibiting hypothalamic TRH expression is its 
feedback inhibition by T3.  Approximately 80% of hypothalamic T3 is derived from 
tanycytes, special ependymal cells located in the floor of the 3rd ventricle.  Tanycytes 
take up T4 from plasma and convert it to T3 by type II deiodinase (Dio2) (159-161).  T3 
travels into the hypothalamus via tanycyte processes extending deep into the 
hypothalamus.  Although plasma levels of T3 and T4 are lower in the Ren1c-/- mice, it is 
possible that hypothalamic Dio2 and thus hypothalamic T3 are elevated in these 
animals, leading to suppression of TRH expression in the hypothalamus.  Indeed the 
levels of hypothalamic T3, Dio2 gene expression and Dio2 activity of the Ren1c-/- mice 
were significantly higher than those of WT mice, and were recapitulated by losartan (Fig. 
3.5A-C).   
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Figure 3.5 Inhibition of Ang II increased Dio2 expression and T3 levels in the 
hypothalamus. A. Dio2 gene expression levels and B. Dio2 activity in the 
hypothalamus. C. Hypothalamic T3 levels. D,  E. Ang II effect on Dio2 expression and 
its mechanism in tanycytes. Cal: calphostin C (10 µM), PKC inhibitor. All values are 
expressed as means ± S.E.M. n=7 *p < 0.05 vs. WT mice or tanycytes without 
treatment. -/-: Ren1c-/- mice, LOS: WT mice treated with losartan (0.45 g/L) for 4 weeks 
or N1 cells treated with losartan (10 nmol/L), and PD: N1 cells treated with PD123319 
(10 nmol/L). 
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 Moreover, Ang II significantly decreased Dio2 expression in primary culture of 
tanycytes, which was inhibited by losartan (10 nmol/L), but not by a type 2 Ang II 
receptor blocker, PD123319 (10 nmol/L) (Fig. 3.5D, E).  A PKC inhibitor calphostin C 
(10 nmol/L) abolished the reduction of Dio2 by Ang II (Fig. 3.5F), indicating that Ang II 
via AT1R-PKC directly suppressed Dio 2 expression in the tanycytes.  I conclude that 
inhibiting RAS causes tertiary hypothyroidism by directly inhibiting Ang II-AT1R-Jak2-
STAT3-TRH pathway in hypothalamic TRH producing cells and by eliminating the 
suppression of Dio2-T3 via AT1R, leading to feedback inhibition of TRH expression by 
increased hypothalamic T3. 
 
Hypothyroidism is responsible for anemia caused by the inhibition of RAS-AT1R. 
Consistent with well documented anemia caused by RAS inhibition (113), the 
Ren1c-/- mice had severe normocytic normochromic anemia (Figs. 3.6A-E; Table 3.2).  
Because RBC volume per body weight of the Ren1c-/- mice was 35% smaller than that 
of WT mice (Fig 3.6H), their low RBC number, hemoglobin and hematocrit were not 
simply due to dilution of the blood by increased plasma volume, but they truly had 
anemia.  The Ren1c-/- mice had normal reticulocyte index in their peripheral blood 
(Figs. 3.6 F, and G; Table 3.2) and normal plasma levels of iron and transferrin (Table 
3.2), excluding hemolytic anemia and iron deficient anemia and suggesting impaired 
erythropoiesis in their bone marrow.   
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Figure 3.6 Inhibition of Ang II does not decrease blood volume, but increased 
plasma volume and decreased red blood cell volume. A. red blood cell (RBC) 
number, B. hemoglobin (Hgb), C. hematocrit (Hct), D. mean corpuscular volume (MCV), 
E. mean corpuscular hemoglobin (MCH), and F, G. reticulocytes in among Ren1c-/- 
mice, WT mice, WT mice treated with losartan or enalapril.  H. blood volume, plasma 
volume and red blood cell volume in All values are expressed as means ± S.E.M. n ≥8 
*p< 0.05 vs. WT mice.. Black bar: WT mice; white bar: Ren1c-/- mice, gray bar: WT 
mice treated with losartan (0.45g/L drinking water), and pink bar: mice treated with 
enalapril (0.3g/L drinking water).   
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Additionally, WT mice treated with losartan or enalapril for two months also had severe 
anemia comparable to the Ren1c-/- mice (Fig. 3.6A-E; Table 3.2), showing that the 
inhibition of AT1R causes anemia. 
As expected administration of Ang II corrected anemia of the Ren1c-/- mice (Figs. 
3.7A-E).  Because a number of studies have shown that thyroid hormone can stimulate 
erythropoiesis in early stages of erythroid progenitor cells (117, 118, 120, 121), and 
because inhibition of RAS causes hypothyroidism as I demonstrated in Chapter 2, I next 
investigated whether low circulating thyroid hormones of the Ren1c-/- mice are 
responsible for their severe anemia.  Administration of T3 (5µg/kg/day) by osmotic 
minipump to the Ren1c-/- mice for two weeks restored their RBC number, Hct, and Hgb 
to the levels comparable to those of WT mice (Figs3.7A-E; Table 3.2) without 
increasing plasma Ang II levels, which were undetectable and not different from zero as 
in the Ren1c-/- mice (not shown), showing that thyroid hormone corrects anemia in the 
Ren1c-/- mice independently of Ang II.  Administration of T3 also corrected anemia of 
WT mice treated with losartan or enalapril (Figs. 3.7A-E; Table 3.2), indicating 
hypothyroidism is responsible for anemia caused by inhibiting AT1R. However, after 
administration of 5µg/kg/day T3 the Ren1c-/- mice, and WT mice with losartan or 
enalapril had two-fold levels of plasma T3 compared to WT mice (~4.0 pg/ml vs. 2.2 
pg/ml in WT mice; Table 3.2).  Erythropoietin is an important stimulator for 
erythropoiesis and is elevated in the Ren1c-/- mice and WT mice treated with losartan 
or enalapril.  Interestingly administration of 5 µg of T3 increased plasma EPO levels 
twice as high as those of WT mice despite the correction of anemia (Table 3.2). This 
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could be because high dose T3 (5µg/kg/day) elevates plasma EPO via Hypoxia induced 
factor (HIF)(162). 
Interestingly, administration of low dose of T3 (300ng/kg/day) for 2 weeks 
corrected anemia and elevated plasma EPO levels of the Ren1c-/- mice and WT mice 
with losartan or enalapril to the levels similar to WT control mice, and the effects of 
5µg/kg/day and 300ng/kg/day T3 to correct anemia caused by inhibiting RAS were 
similar (Fig. 3.7, Table 3.2).  Low dose T3 increased plasma T3 levels of the Ren1c-/- 
mice to the levels indistinguishable from those of WT control mice (Table 3.2). 
Importantly, although Ang II is known to increase EPO(147), high dose EPO 
(5000 IU) did not correct anemia of the Ren1c-/- mice (Figs. 3.7 A-E; table 3.2), while 
the same dose of EPO increased RBC number, hemoglobin and hematocrit in WT mice 
(Figs. 3.7 A-E; table 3.2), showing that anemia of the Ren1c-/- mice is resistant to EPO. 
To address the contribution of direct effect on erythropoiesis of Ang II independent of 
thyroid hormone, I treated WT mice with a thyroid hormone synthesis blocker 
methimazole (MMI) together with an iodine uptake blocker sodium perchlorate (NaClO4) 
for 2 months, and tested the effect of Ang II on anemia of these animals.  WT mice 
treated with MMI and NaClO4 had undetectable levels of circulating thyroid hormones, 
and microcytic hypochromic anemia, which was corrected by administration of T3 
(5µg/kg/day) (Table 3.2). Administration of Ang II to these animals did not correct 
anemia caused by MMI, although the same dose of Ang II corrected anemia of the 
Ren1c-/- mice (Table 3.2).   
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Figure 3. 7 Inhibition of Ang II causes anemia, while T3 restores it. A. RBC number, 
B. hematoglbin (Hgb), C. hematocrit (HCT), D. MCV,  E. MCH, and F, G. plasma EPO 
levels in Ren1c-/- mice, WT mice, WT mice treated with losartan or enalapril with T3 
(5µg/kg/day) or Ang II (7.5µg/kg/day) or human EPO (5000 U/ kg/day) for two weeks. 
Ren1c-/- mice also treated with low dose T3 (300 ng/kg/day) for 2 weeks. All values are 
expressed as means ± S.E.M. n=8 *p< 0.05 vs. WT mice. 
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In addition, although MMI+NaClO4 caused hypothyroidism and anemia, plasma 
EPO levels stayed similar to the levels of WT control mice, indicating that thyroid 
hormone-independent effect of Ang II on anemia caused by RAS inhibition is small and 
insufficient to correct the anemia. 
I conclude that inhibiting RAS causes normocytic normochromic anemia that low 
dose thyroid hormone is sufficient to correct this anemia, and that direct effects of Ang II 
independent of thyroid hormone are insufficient to correct this anemia. 
 
Inhibition of RAS-AT1R impairs early stage erythropoiesis in the bone marrow. 
Because the bone marrow is the main organ for erythropoiesis in adults, I 
counted the number of cells in the bone marrow.  The bone marrow of the Ren1c-/- 
mice had 35% lower cell number than that of WT mice, and that of WT mice treated with 
losartan or enalapril had 25% lower cell number than WT mice (Fig 3.8A).  Moreover, 
the numbers of their burst-forming unit erythroid (BFU-E) and colony-forming unit 
erythroid (CFU-E) colonies obtained from the culture of the bone marrow cells of the 
Ren1c-/- mice were lower than those of WT mice, and administration of T3 corrected 
the numbers of these colonies to WT control levels (Figs. 3.8B-C). Inhibition of thyroid 
hormone synthesis by MMI and NaClO4 decreased the numbers of bone marrow cells 
and of BFU-E and CFU-E colonies, which was corrected by T3 but not by Ang II or 
human EPO, indicating that thyroid hormone is required but Ang II is dispensable for 
early stage of erythropoiesis in the bone marrow. 
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Figure 3.8  Inhibition of Ang  II causes decreased early stage of erythroid 
progenitor cells in bone marrow. A. Cell number count in the bone marrow from both 
femurs of each mouse. B. blast forming unit-erythroid (BFU-E), and C. Colony forming 
unit-erythroid (CFU-E) cell number in the Ren1c-/- mice, WT mice, WT mice treated with 
losartan or enalapril. All values are expressed as means ± S.E.M. n=7 *p< 0.05 vs. WT 
mice. -/-: Ren1c-/- mice, LOS: WT mice treated with losartan (0.45g/L in drinking water) 
for 2 months, ENA: mice treated with enalapril (0.3g/L in drinking water) for two months, 
and MMI: WT mice treated with methimazole (2g/L in drinking water) for two months.  
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Figure 3.9 Inhibition of Ang II decreases erythroid progenitor cells positive for 
surface markers CD71 and ter119, and T3 corrects it. A. FACS of bone marrow cells 
in the Ren1c-/- mice, WT mice, WT mice treated with losartan or enalapril.  B FACS of 
bone marrow cells after administration of T3 (5µg/kg/day) for two weeks. C. percentage 
of CD 71, and D. ter119 without or with administration of T3 in the Ren1c-/- mice, WT 
mice, WT mice treated with losartan or enalapril. All values are expressed as means ± 
S.E.M. n=5 *p< 0.05 vs. WT mice.  -/-: Ren1c-/- mice, LOS: WT mice treated with 
losartan (0.45g/L in drinking water) for 2 months, ENA: mice treated with enalapril 
(0.3g/L in drinking water) for two months, and MMI: WT mice treated with methimazole 
(2g/L in drinking water) for two months. 
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To investigate which stage of erythroblast differentiation is affected by thyroid 
hormone, I used flow cytometry and labeled CD71 antibody to early stage of labeled 
and ter119 to late stage of erythroblast. Interestingly, the Ren1c-/- mice and WT mice 
treated with losartan or enalapril had significantly reduced number of CD71 and ter119 
positive bone marrow cells, indicating decreased early stage erythroblasts in these mice 
compared to WT control mice (Fig. 3.9A, 3.9C, 3.9D).  
Administration of T3 increased CD71 and ter11 positive cells in the bone marrow 
of the Ren1c-/- mice and of WT mice treated with losartan or enalapril to the levels of 
WT control mice, showing that T3 increased the number of early stage of erythroblast 
(Fig. 3.9B-D).  Inhibition of thyroid hormone synthesis decreased the numbers of CD71 
and ter119 positive cells in the bone marrow, which was corrected by T3 but not by Ang 
II.  Although the spleen can contribute to erythropoiesis in anemia, the weight, histology 
(red pulp and white pulp), and cell number in the spleen was indistinguishable from 
those of WT mice (not shown). 
I conclude that hypothyroidism is the predominant cause of anemia induced by 
inhibiting RAS, and that thyroid hormone is required but Ang II is dispensable for early 
stage of erythropoiesis in the bone marrow (Fig. 3.10). 
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Figure 3.10 The mechanism of inhibition of Ang II causes anemia through 
inhibiting thyroid hormone pathway.  
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Table 3.1: Characteristics of 4-month-old male mice plasma thyroid hormones & TSH 
levels 
Groups fT3 (pg/ml) fT4 (ng/dl) TSH levels (ng/ml) 
Wild type (n=12)     2.2 ± 0.2     1.10 ± 0.04     1.5 ± 0.2 
Ren1c-/- (n=10)     1.3 ± 0.2 *     0.42 ± 0.02 *     0.6 ± 0.1 * 
WT+LOS (n=7)     1.4 ± 0.2 *     0.71 ± 0.05 *     0.9 ± 0.1 * 
WT+ENA (n=7)     1.6 ± 0.3 *     0.80 ± 0.06 *     0.9 ± 0.2 * 
Ren1c-/-+Ang II (n=5) 
    2.1 ± 0.2     0.95 ± 0.03     1.3 ± 0.2 
Ren1c-/-+ hREN(n=5)           1.5 ± 0.3 *                  0.62 ± 0.02 *                    0.8 ± 0.2 * 
Ren1c-/-+TRH (n=7) 
    2.0 ± 0.3     0.91 ± 0.02 *     1.2 ± 0.3 
WT+LOS +TRH (n=7)     2.4 ± 0.3     1.22 ± 0.05     1.5 ± 0.3 
WT+ENA +TRH (n=7     2.4 ± 0.3     1.20 ± 0.04     1.6 ± 0.4 
WT+MMI/NaClO4  (n=8)     ND     ND     ND 
WT+MMI/NaClO4+Ang II(n=6)     ND     ND     ND 
 
 
 
 
 
 
Data are given as mean ±SEM. fT3: free thyronine, fT4: free thyroxine, TSH: thyroid-stimulating 
hormone, Ang II: angiotensin II (7.5µg/kg/day) for 2 weeks, hREN: human renin (0.1µg/kg/day) for 
2 weeks. LOS: WT mice treated with losartan(0.45g/L in drinking water) for 4 weeks, ENA: mice 
treated with enalapril (0.3g/L in drinking water) for 4 weeks. TRH : mice treated with TRH 
(5µg/kg)for one hour. *p < 0.05 vs. wild type. ND: non-detectable, the free T3 and T4 value under 
0.05 pg/ml and 0.05 ng/dl. 
 Table 3.2: Hematologic indices of 4-month old male mice  
Groups RBC 
(106/mm3) 
Hgb 
(g/dl) 
Hct 
(%) 
MCV 
(fl/cell) 
MCH 
(pg/cell) 
plasma iron 
(µg/dl) 
transferrin 
(mg/ml) 
free T3 
(ng/ml) 
Plasma EPO 
(pg/ml) 
Wild type (n=12)   9.3 ± 0.2 14.4 ± 0.3 38.6 ± 0.7 42.4 ± 0.8 15.2 ± 0.1 120 ± 12 3.0 ± 0.2 2.3 ± 0.1   343 ± 42 
Ren1c-/- (n=12)   6.9 ± 0.2* 10.5 ± 0.3* 29.6 ± 1.0* 41.3 ± 0.7 14.7 ± 0.2 110 ± 15 3.4 ± 0.4 1.3 ± 0.2*   583 ± 70* 
WT+LOS (n=10)   7.6 ± 0.2* 11.5 ± 0.3* 31.3 ± 0.8* 41.9 ± 0.2 15.1 ± 0.1 114 ± 4.0 3.0 ± 0.1 1.4 ± 0.2*   450 ± 42* 
WT+ENA (n=10)   7.5 ± 0.3* 11.4 ± 0.3* 30.0 ± 1.2* 40.4 ± 0.2 14.7 ± 0.1 116 ± 7.0 3.0 ± 0.2 1.6 ± 0.3*   526 ± 80* 
MMI (n=10)   8.0 ± 0.1* 12.0 ± 0.3* 32.2 ± 1.2* 38.6 ± 0.7* 14.1 ± 0.1* 150 ± 6.0* 2.9 ± 0.2      ND   280 ± 38 
Ren1c-/-+ HT3 (n=10)      9.4 ± 0.3 13.4 ± 0.5 36.3 ± 1.2* 40.9 ± 0.5 15.0 ± 0.2 - - 3.9 ± 0.6* 1032 ± 182* 
WT+LOS + HT3 (n=8)   9.2 ± 0.2 13.5 ± 0.2 40.0 ± 1.2 43.0 ± 0.7 14.7 ± 0.2 - - 4.0 ± 0.5*   765 ± 50* 
WT+ENA + HT3(n=8)   9.3 ± 0.1 13.4 ± 0.1 39.0 ± 0.9 42.3 ± 0.8 14.6 ± 0.2 - - 3.9 ± 0.5* 1035 ± 170* 
Ren1c-/-+ LT3 (n=6)        9.0 ± 0.3 13.4 ± 0.3 37.1 ± 1.0 40.0 ± 0.4 14.5 ± 0.1   2.2 ± 0.2   384 ± 40 
WT+LOS + LT3 (n=6)   9.3 ± 0.2 13.8 ± 0.4 37.2 ± 1.5 40.4 ± 0.2 14.9 ± 0.3   2.4 ± 0.3   285 ± 26 
WT+ENA + LT3(n=6)   9.2 ± 0.1 13.7 ± 0.4 37.8 ± 1.2 41.0 ± 0.7 14.7 ± 0.2   2.4 ± 0.2   343 ± 40 
Ren1c-/-+ AII (n=7)   9.1 ± 0.3 13.9 ± 0.3 39.4 ± 1.0 40.4 ± 0.6 14.5 ± 0.5 - - 2.1 ± 0.2   410 ± 45 
MMI+ AII (n=7)   9.2 ± 0.1 12.8 ± 0.1* 33.4 ± 0.3* 38.1 ± 0.7* 13.8 ± 0.2* - -      ND   312 ± 31 
MMI+ T3 (n=7)   9.0 ± 0.2 13.8 ± 0.2 36.9 ± 0.6 42.4 ± 0.3 15.4 ± 0.1 122 ± 10 3.1 ± 0.2 3.3 ± 0.7*   545 ± 80* 
WT+EPO (n=7) 10.5 ± 0.2* 16.1 ± 0.1* 46.3 ± 1.6* 44.0 ± 2.0 15.3 ± 0.2 - - 2.4 ± 0.1 - 
Ren1c-/-+EPO (n=7)        6.8 ± 0.2 10.3 ± 0.2 29.3 ± 1 43.3 ± 1.2 15.2 ± 0.1 - - 1.1 ± 0.3* - 
 
Data are given as mean ±SEM. Hgb: Hemoglobin, Hct: hematocrit, MCV: Mean Corpuscular Volume, MCH: Mean Corpuscular 
Hemoglobin. LOS: WT mice treated with losartan(0.45g/L in drinking water) for 2 months, ENA: mice treated with enalapril (0.3g/L in 
drinking water) for two months, and MMI: WT mice treated with methimazole (2g/L in drinking water) for two months;  HT3: high dose of T3 
(5µg/kg/day), and LT3: low dose of T3 (300 ng/kg/day) for 2 weeks, Ang II: angiotensin II (7.5µg/kg/day) for 2 weeks, LOS: WT mice treated 
with losartan(0.45g/L in drinking water) for 4 weeks, ENA: mice treated with enalapril (0.3g/L in drinking water) for 4 weeks. EPO: mice 
treated with EPO (5000 U/kg/day; i.p) for two weeks.  *p < 0.05 vs. wild type. ND: non-detectable, the free T3 and T4 value under 0.05 
pg/ml and 0.05 ng/dl. 
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DISCUSSIONS 
In this study I have shown that inhibiting RAS causes tertiary hypothyroidism by 
reducing the effect of Ang II via AT1R to directly stimulate TRH via JAK2-STAT3 
pathway, and by increasing Dio2 and T3 in the hypothalamus and augmenting feedback 
inhibition of TRH.  I also demonstrated that hypothyroidism is the predominant cause of 
anemia induced by inhibiting RAS, and that thyroid hormone is required but Ang II is 
dispensable for early stage of erythropoiesis in the bone marrow.  Although inhibitors of 
RAS such as ARB, ACE inhibitors and renin inhibitors are widely prescribed for the 
treatment of hypertension, hypothyroidism is not known as their side effect.  We believe 
that there are a lot of patients with hypothyroidism due to treatment with RAS inhibitors, 
but many of them are probably overlooked.  This is simply because RAS-inhibitor-
induced hypothyroidism is difficult to detect by at least two reasons: 1) The doctors are 
screening hypothyroidism by expecting an increase in TSH. However, in tertiary 
hypothyroidism caused by RAS inhibition TSH and TRH decrease.  2) Low body 
temperature is considered to be the most sensitive method to detect hypothyroidism, 
but it is difficult to detect unless the measurement is carried out after fasting as Dr. 
Broda Barness suggested (163). This is probably because fasting decreases leptin(164) 
resulting in decreased TRH expression, which probably makes it easier to detect the 
changes in body temperature.  It is therefore important to measure body temperature as 
a first thing in the morning in the bed before any activity. The values taken at outpatient 
clinic may not be sensitive enough to detect low body temperature caused by 
hypothyroidism. 
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Patients with hypothyroidism reported to have various types of anemia including 
iron deficient anemia and macrocytic anemia. Our data show that inhibiting RAS causes 
normocytic, normochromic anemia without decreasing reticulocyte index, plasma iron 
and transferrin (Fig. 3.6A-H; Table 3.2).  However, WT mice that were made profoundly 
hypothyroid by MMI and NaClO4 have microcytic and hypochromic anemia, which was 
corrected by administration of T3 (Fig. 3.7A-G; Table 3.2). These data suggest that 
mild hypothyroidism caused by inhibiting RAS leads to normocytic normochromic 
anemia, but if thyroid hormones decrease further patients likely develop microcytic 
hypochromic anemia. Various kinds of anemia in patients with hypothyroidism could be 
due to the severity of hypothyroidism and to concomitant conditions other than 
hypothyroidism. 
We used high doses of losartan and enalapril that decrease BP to the levels of 
the Ren1c-/- mice, which clearly manifested hypothyroidism and anemia. However, 
because it is not widely known that RAS inhibition causes anemia despite these drugs 
are widely used for the treatment of hypertension, anemia caused by RAS inhibition 
does not seem to be clinically relevant in the majority of hypertensive individuals who do 
not have other complications. However, if RAS is inhibited in patients with subclinical or 
overt hypothyroidism, hypothyroidism is likely exacerbated and the patients may 
develop anemia with relatively low doses of RAS. Although Ang II is known to increase 
EPO (147), the Ren1c-/- mice, and WT mice administered with losartan or enalapril all 
showed increased EPO probably in response to anemia because correcting anemia 
using T3 reduced EPO back to WT control levels (Fig. 3.7F,G). Administration of EPO 
increased Hct of WT mice but not in the Ren1c-/- mice, indicating the Ren1c-/- mice are 
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EPO resistant.  Therefore, in patients with chronic kidney disease who have reduced 
capability of producing EPO and often have high BP, inhibiting RAS is expected to 
easily cause clinically relevant anemia. Because T3 corrects RAS-inhibition-induced 
anemia independently of Ang II, using low dose thyroid hormone to correct 
hypothyroidism as an adjunct therapy will be useful to reduce the dose of EPO for the 
treatment of anemia, to correct EPO resistance, to minimize the side effects of EPO, 
and to improve anemia and long-term prognosis and quality of life of patients with 
chronic renal failure. However, we should be cautious not to administer too much 
thyroid hormone to correct hypothyroidism caused by RAS inhibition, because 
hyperthyroidism increases EPO and possibly its side effects. 
  
 
 
 
Chapter 4: Summary, Perspectives, and Concluding Remarks 
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SUMMARY AND CONCLUSION 
An overactive RAS is suggested to worsen the metabolic syndrome, and an 
inhibition of RAS causes severe anemia.  Our previous study has demonstrated that 
mice lacking renin (Ren1c-/-) are lean and insulin sensitive. To our surprise, the Ren1c-
/- mice have low circulating total thyroid hormones, and their plasma catecholamine 
levels were similar to those of WT mice.  Although Ang II is suggested to contribute the 
metabolic syndrome, the precise mechanisms are not completely understood.  Obesity 
is often associated with leptin resistance, and improving leptin sensitivity is a potential 
therapeutic strategy to treat obesity.  This dissertation has investigated whether 
inhibiting RAS improves leptin sensitivity, and whether and how inhibiting RAS causes 
hypothyroidism and anemia. 
The main approach in Chapter 2 to investigate the effects of inhibiting RAS on 
leptin and insulin sensitivity is the generation and use of mice lacking both renin and 
leptin (Ren1c-/-;ob/ob).  Because lower plasma leptin levels of the Ren1c-/- mice can 
improve leptin sensitivity, this strategy allows me to test leptin sensitivity with the same 
basal levels of leptin.  I also investigated the role of Ang II and Ang II-independent of 
renin effects on lean phenotype and insulin sensitivity of the Ren1c-/- mice by 
administering the Ren1c-/- mice with Ang II or human renin, and blockade of AT1R of 
WT mice by losartan.  In Chapter 3, I investigated why the Ren1c-/- mice have low 
circulating total thyroid hormones and severe anemia.  To achieve this goal, I used the 
Ren1c-/- mice, and WT mice administered with an AT1R blocker losartan, or an Ang 
converting enzyme inhibitor enalapril, as well as anti-thyroid drug, methimazole. 
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Leptin sensitivity of the Ren1c-/- mice 
The Ren1c-/-;ob/ob mice had smaller body weight and fat mass than the ob/ob 
mice despite their fat mass/BW ratio was indistinguishable from that of the ob/ob mice.  
This phenotype is associated with increased fecal fat excretion and fatty acid oxidation.  
Compared to the ob/ob mice, the Ren1c-/-;ob/ob mice, and the ob/ob mice treated with 
losartan showed greater loss of body weight, and fat mass by administration of 
exogenous leptin due to suppression of food intake, which is consistent with changes in 
the levels of hypothalamic expression of POMC, NPY, and AgRP, and low expression of 
SOCS3 in the hypothalamus.  Indeed, mice lacking SOCS3 in POMC expressing cells 
have increased leptin sensitivity and decreased BW and food intake due to elevated 
levels of hypothalamic POMC expression in the hypothalamus (79).  Thus, inhibition of 
RAS improves leptin sensitivity and provides a novel target to treat obesity. 
Interestingly, fecal fat excretion markedly increased by leptin infusion in the 
Ren1c-/-;ob/ob mice.  This result is consistent with the finding that leptin directly inhibits 
both secretion and intracellular activity of pancreatic lipase(142).  Because the Ren1c-/-
;ob/ob mice had only 25% WT expression of pancreatic lipase and colipase, 
administration of leptin further decreased pancreatic lipase, leading to more fecal fat 
loss and smaller BW.  
The Ren1c-/-;ob/ob mice had increased fatty acid oxidation.  This is consistent 
with decreased RER in the indirect calorimetry, and increased expressions of PPAR-α, 
ACOX1, and CPT-1 in the liver.  CPT-I is the rate limiting step in fatty acid oxidation and 
regulated by AMPK(165).  AMPKα activity of the Ren1c-/-;ob/ob mice was markedly 
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increased in the liver.  A number of studies have showed that AMPKα plays an 
important role in the regulation of fatty acid oxidation via CPT1 and improves non-
alcoholic fatty liver disease (NFLD)(166).  This is also consistent with reduced liver 
triglyceride content and ALT and AST levels of the Ren1c-/-;ob/ob mice.  Increased 
plasma adiponectin of the Ren1c-/-;ob/ob mice likely contributes to these results 
because adiponectin increased fatty acid oxidation via AMPK(167), and because Ang II 
decreases adiponectin production in 3T3-L1 adipocytes and losartan inhibits it (Li et al., 
our unpublished observation).  WT or the ob/ob mice treated with losartan had 
significantly increased plasma adiponectin concentrations.  Accordingly, Ang II plays an 
important role in fatty acid oxidation. 
 
Insulin sensitivity of the Ren1c-/- mice. 
The Ren1c-/- mice and the Ren1c-/-;ob/ob mice have low plasma glucose 
concentrations and insulin levels by OGTT, have larger decrease in plasma glucose 
levels by ITT, and their gluconeogenesis was less by PTT compared with WT mice and 
ob/ob mice, respectively.  Increased plasma adiponectin likely contributes to these 
results because adiponectin improves insulin sensitivity (143), and because WT or the 
ob/ob mice treated with losartan had significantly increased plasma adiponectin 
concentrations.  They had improved glucose tolerance and insulin sensitivity, and had 
reduced gluconeogenesis similar to those of the Ren1c-/- mice and the Ren1c-/-;ob/ob 
mice, suggesting the contribution of the mechanism(s) independent of leptin.  
Interestingly, chronic leptin administration improved insulin sensitivity in the ob/ob mice, 
but not in the Ren1c-/-;ob/ob mice and the ob/ob mice treated with losartan.  This may 
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be because chronic leptin administration increased plasma adiponectin levels in the 
ob/ob mice, but not in the Ren1c-/-;ob/ob mice and the ob/ob mice treated with losartan, 
simply because adiponectin production reached maximum levels by inhibiting RAS, and 
further stimulation by leptin does not increase adiponectin anymore.  Accordingly, 
increased fatty acid oxidation and suppression of gluconeogenesis when RAS is 
inhibited is likely due to increased plasma adiponectin. 
 
Hypothyroidism of the Ren1c-/- mice. 
Mice lacking renin have low circulating thyroid hormones.  In this dissertation I 
have shown that inhibiting Ang II-AT1R causes tertiary hypothyroidism by reducing the 
effect of Ang II to directly stimulate TRH via JAK2-STAT3 pathway.  Both Ang II and 
leptin enhance JAK2-STAT3 signaling pathway, which in turn increases hypothalamic 
expression of TRH.  Although the Ren1c-/- mice have low plasma leptin levels 
comparable to the ob+/- mice, the TRH levels in the hypothalamus of the ob+/- mice 
were indistinguishable from those of WT mice, indicating that the reduced leptin levels 
in the Ren1c-/- mice are unlikely the cause of decreasing hypothalamic TRH levels.  
Moreover, the Ren1c-/- mice and WT mice treated with losartan had increased Dio2 and 
T3 in the hypothalamus causing decreased hypothalamic expression of TRH, which 
results in hypothyroidism. 
 
Anemia of the Ren1c-/- mice due to hypothyroidism 
Anemia often occurs in hypothyroidism. I demonstrated that hypothyroidism 
caused by RAS inhibition causes anemia.  Although Ang II and thyroid hormone have 
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shown to stimulate BFU-E and CFU-E, the precise mechanism is not known. In chapter 
3 I have shown that inhibition of Ang II causes tertiary hypothyroidism.  Interestingly, I 
also found that the Ren1c-/- mice have severe anemia. To investigate whether the 
Ren1c-/- mice cause impaired erythropoiesis by low circulating thyroid hormone, I 
administered low dose T3 (300ng/kg/day) or high dose T3 (5ug/kg/day) to the Ren1c-/- 
mice for two weeks. Anemia of the Ren1c-/- mice was corrected by both low and high 
doses of T3.  Plasma thyroid hormone levels of the Ren1c-/- mice treated with low dose 
T3 were similar to those of WT mice.  These results were replicated by losartan and 
enalapril.  This result demonstrates that inhibition of AT1R activation causes anemia via 
hypothyroidism.  To address the contribution of the direct Ang II effect on erythropoiesis, 
I administered Ang II to MMI-induced hypothyroid mice.  Although their RBC number 
was indistinguishable from that of WT mice, Hgb and Hct were still lower than those of 
WT mice. In contrast, the Ren1c-/- mice treated with Ang II corrected anemia.  Similar to 
thyroid hormone receptor TRα-/- mice, the Ren1c-/- mice have impaired erythropoiesis 
in the bone marrow.  Taken together, thyroid hormone plays an important role in the 
erythropoiesis and provides a novel therapeutic strategy to treat anemia caused by RAS 
inhibition. 
 
PERSPECTIVES AND CONCLUDING REMARKS 
In this dissertation I have investigated the role of Ang II in leptin sensitivity, 
thyroid function, and erythropoiesis.  Although Ang II plays an important role in the 
regulation of the metabolic syndrome and inhibition of RAS causes anemia, several 
points deserve further research. 
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In chapter 2, I have demonstrated that the Ren1c-/- mice have increased fatty 
acid oxidation and fecal fat excretion.  Although increased fecal fat excretion is due to 
decreased expressions of pancreatic lipase and colipase, the role of Ang II in the 
regulation of pancreatic lipase and colipase levels is still not completely understood.  
Adiponectin likely plays an important role in fatty acid oxidation and insulin sensitivity of 
the Ren1c-/-;ob/ob mice.  Increased fatty acid oxidation and suppression of 
gluconeogenesis of the Ren1c-/-;ob/ob mice is likely due to increased liver AMPKα 
activity, However, whether lean phenotype of the Ren1c-/- mice is due to increased 
adiponectin is still not understood.  
In chapter 3, I have shown that the inhibition of RAS causes tertiary 
hypothyroidism.  I believe there are a lot of patients with hypothyroidism due to 
treatment with RAS inhibitors.  Many of them are probably overlooked.  This is simply 
because detecting RAS-inhibitor-induced hypothyroidism is difficult to detect by at least 
two reasons: 1) many doctors are screening hypothyroidism by expecting an increase in 
TSH, which does not happen by RAS inhibition, because it causes tertiary 
hypothyroidism, and thus TSH becomes low instead of high. 2) Low body temperature is 
considered to be a most sensitive method to detect hypothyroidism, but it is difficult to 
detect unless the measurement is carried out after fasting as Dr. Broda Barness 
suggested (163). I first measured rectal temperature of mice without fasting, and was 
not able to detect significant difference between the Ren1c-/- mice and WT control mice.  
However, when I measured rectal temperatures of leptin deficient Ren1c-/-;ob/ob mice, I 
was able to easily detect lower rectal temperatures of the Ren1c-/-;ob/ob mice 
compared to those of the ob/ob mice without fasting.  The reduction of rectal 
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temperature by cold exposure was bigger in the Ren1c-/-;ob/ob mice than in the ob/ob 
mice. Thus, it is important to measure body temperature in human individuals after 
fasting at rest in the morning.  
I have also shown  that hypothyroidism is the predominant cause of anemia 
induced by inhibiting RAS, and that without correcting hypothyroidism Ang II is not 
sufficient to correct anemia caused by RAS inhibition.  Administration of EPO increased 
Hct of WT mice but not in the Ren1c-/- mice, indicating the Ren1c-/- mice are EPO 
resistant.  Therefore, in patients with chronic kidney disease who have reduced 
capability of producing EPO and often have high BP, inhibiting RAS is expected to 
easily cause clinically relevant anemia.  Because T3 corrects RAS-inhibition-induced 
anemia independently of Ang II, using low dose thyroid hormone to correct 
hypothyroidism as an adjunct therapy will be useful to reduce the dose of EPO for the 
treatment of anemia, to correct EPO resistance, to minimize the side effects of EPO, 
and to improve anemia and long-term prognosis and quality of life of patients with 
chronic renal failure.   
Overall, in these studies, I have demonstrated that the lack or decrease in Ang II 
or its effects increase fatty acid oxidation and fecal fat excretion, and improve leptin and 
insulin sensitivity.  My results provide scientific basis for inhibiting RAS as a treatment of 
diabetes and obesity.  Although inhibition of RAS has great benefit in diabetes and 
obesity, it causes tertiary hypothyroidism and anemia.  Thyroid hormone is a potential 
therapeutic strategy for anemia of patients with chronic renal failure, who are treated 
with inhibitors for RAS.  However, caution should be paid to hypothyroidism when using 
high dose of inhibitors of RAS. 
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